As
filed with the Securities and Exchange Commission on August 24, 2020
Registration
No. 333-
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
S-3
REGISTRATION
STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
CohBar,
Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
26-1299952
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
1455
Adams Drive, Suite 2050
Menlo
Park, California
94025
(650)
446-7888
(Address,
including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Steven
Engle
Chief
Executive Officer
CohBar,
Inc.
1455
Adams Drive, Suite 2050
Menlo
Park, California
94025
(650)
446-7888
(Name,
address, including zip code, and telephone number, including area code, of agent for service)
Copies
to:
Amanda Rose, Esq.
Chelsea Anderson, Esq.
Fenwick & West LLP
1191 Second Avenue, Floor 10
Seattle, Washington
98101
(206) 389-4510
|
|
Jeff Biunno
Chief Financial Officer
CohBar, Inc.
1455 Adams Drive, Suite 2050
Menlo Park, California
94025
(650) 446-7888
|
Approximate
date of commencement of proposed sale to the public: From time to time after the effective date of this Registration Statement.
If
the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please
check the following box: ☐
If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under
the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check
the following box: ☒
If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please
check the following box and list the Securities Act registration statement number of the earlier effective registration statement
for the same offering: ☐
If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list
the Securities Act registration statement number of the earliest effective registration statement for the same offering: ☐
If
this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become
effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐
If
this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I. D. filed to register
additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following
box. ☐
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):
Large
accelerated filer
|
☐
|
Accelerated
filer
|
☐
|
Non-accelerated
filer
|
☒
|
Smaller
reporting company
|
☒
|
Emerging
growth company
|
☒
|
|
|
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.
☐
CALCULATION
OF REGISTRATION FEE
Title of Each Class of Securities to be
Registered(1)
|
|
Amount
to be
Registered(1) (2)
|
|
|
Proposed
Maximum
Offering Price
Per Security(3)
|
|
|
Proposed
Maximum
Aggregate
Offering Price(3)
|
|
|
Amount of
Registration Fee(4)
|
|
Common stock, $0.001 par value per share
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred stock, $0.001 par value per share
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt securities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Subscription rights
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Units
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
|
|
|
|
|
|
|
$
|
100,000,000
|
|
|
$
|
3,583.07
|
|
(1)
|
There is being registered hereunder an indeterminate number of shares of (a) common stock, (b) preferred stock, (c) debt securities, (d) warrants to purchase common stock, preferred stock or debt securities of the Registrant, (e) subscription rights to purchase common stock, preferred stock or debt securities of the Registrant, and (f) units, consisting of some or all of these securities in any combination, as may be sold from time to time by the Registrant. Any securities registered hereunder may be sold separately or as units with other securities registered hereunder. There is also being registered hereunder an indeterminate number of shares of common stock, preferred stock and debt securities as shall be issuable upon conversion, exchange or exercise of any securities that provide for such issuance. In no event will the aggregate offering price of all types of securities issued by the Registrant pursuant to this registration statement exceed $100,000,000.
|
(2)
|
Pursuant to Rule 416(a), this registration statement also covers any additional securities that may be offered or issued in connection with any stock split, stock dividend or similar transaction.
|
(3)
|
The proposed maximum offering price per share and proposed maximum aggregate offering price for each type of security will be determined from time to time by the Registrant in connection with the issuance by the Registrant of the securities registered hereunder.
|
(4)
|
Calculated pursuant to Rule 457(o) under the Securities Act of 1933, as amended. Pursuant to Rule 415(a)(6) under the Securities Act, the Registrant hereby offsets the total registration fee due under this Registration Statement by the amount of the filing fee associated with the unsold securities from the Registrant’s Form S-3 Registration Statement, filed with the Securities and Exchange Commission, or the SEC, on November 22, 2017 (SEC File No. 333-221724), and declared effective by the SEC on December 1, 2017 (the “Prior Registration Statement”), which included $100,000,000 of shares of (a) common stock, (b) preferred stock, (c) warrants to purchase common stock or preferred stock of the Registrant, and (d) units, consisting of some or all of these securities in any combination, as may be sold from time to time by the Registrant, or collectively, the Shelf Securities, of which $75,477,337 of the Shelf Securities remain unsold as the date of filing of this Registration Statement. The Registrant has determined to include in this Registration Statement the unsold Shelf Securities under the Prior Registration Statement having an aggregate offering price of $75,477,337, or the Unsold Securities. The associated filing fee of $9,396.93 for the Unsold Securities under the Prior Registration Statement is hereby used to partially offset the current registration fee due, resulting in an additional registration fee of $3,583.07 due in connection with the filing of this Registration Statement, which has been paid in connection with the filing of this Registration Statement. To the extent that, after the filing date hereof and prior to the effectiveness of this Registration Statement, the Registrant sells any Unsold Securities pursuant to the Prior Registration Statement, the Registrant will identify in a pre-effective amendment to this Registration Statement the updated amount of Unsold Securities from the Prior Registration Statement to be included in this Registration Statement pursuant to Rule 415(a)(6) under the Securities Act and the updated amount of securities to be registered on this Registration Statement. Pursuant to Rule 415(a)(6) under the Securities Act, the offering of the Unsold Securities under the Prior Registration Statement will be deemed terminated as of the date of effectiveness of this Registration Statement.
|
The
Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until
the Registrant shall file a further amendment which specifically states that this registration statement shall thereafter become
effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall
become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.
EXPLANATORY
NOTE
This
registration statement contains two prospectuses:
|
●
|
a
base prospectus, which covers the offering, issuance and sale by us of up to $100,000,000 of our common stock, preferred stock,
debt securities, warrants to purchase our common stock, preferred stock or debt securities, subscription rights to purchase
our common stock, preferred stock or debt securities and/or units consisting of some or all of these securities; and
|
|
●
|
a
sales agreement prospectus covering the offering, issuance and sale by us of up to a maximum aggregate offering price of $15,477,192
of our common stock that may be issued and sold under a sales agreement with Virtu Americas LLC. As of August 24, 2020, we
have sold 2,350,067 shares of our common stock for gross proceeds of $4.5 million under the sales agreement.
|
The
base prospectus immediately follows this explanatory note. The specific terms of any securities to be offered pursuant to the
base prospectus will be specified in a prospectus supplement to the base prospectus. The sales agreement prospectus immediately
follows the base prospectus. The $15,477,192 of common stock that may be offered, issued and sold under the sales agreement prospectus
is included in the $100,000,000 of securities that may be offered, issued and sold by us under the base prospectus.
The
information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement
filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities, and
it is not soliciting an offer to buy these securities, in any jurisdiction where the offer or sale is not permitted.
SUBJECT
TO COMPLETION, DATED AUGUST 24, 2020
PROSPECTUS
$100,000,000
CohBar,
Inc.
Common
Stock, Preferred Stock,
Debt
Securities, Warrants, Subscription Rights and Units
From
time to time, we may offer up to $100,000,000 aggregate dollar amount of shares of our common stock or preferred stock, debt securities,
warrants to purchase our common stock, preferred stock or debt securities, subscription rights to purchase our common stock, preferred
stock or debt securities and/or units consisting of some or all of these securities, in any combination, together or separately,
in one or more offerings, in amounts, at prices and on the terms that we will determine at the time of the offering and which
will be set forth in a prospectus supplement and any related free writing prospectus. The prospectus supplement and any related
free writing prospectus may also add, update or change information contained in this prospectus. The total amount of these securities
will have an initial aggregate offering price of up to $100,000,000.
You
should read this prospectus, the information incorporated, or deemed to be incorporated, by reference in this prospectus, and
any applicable prospectus supplement and related free writing prospectus carefully before you invest.
Our
common stock is traded on the Nasdaq Capital Market under the symbol “CWBR.” On August 21, 2020 the last reported
sales price for our common stock was $1.40 per share. None of the other securities we may offer are currently traded on any securities
exchange. The applicable prospectus supplement and any related free writing prospectus will contain information, where applicable,
as to any other listing on the Nasdaq Capital Market or any securities market or exchange of the securities covered by the prospectus
supplement and any related free writing prospectus.
An
investment in our securities involves a high degree of risk. You should carefully consider the information under the heading “Risk
Factors” beginning on page 3 of this prospectus before investing in our securities.
Common
stock, preferred stock, debt securities, warrants, subscription rights and/or units may be sold by us to or through underwriters
or dealers, directly to purchasers or through agents designated from time to time. For additional information on the methods of
sale, you should refer to the section entitled “Plan of Distribution” in this prospectus. If any underwriters, dealers
or agents are involved in the sale of any securities with respect to which this prospectus is being delivered, the names of such
underwriters or agents and any applicable fees, discounts or commissions, details regarding over-allotment options, if any, and
the net proceeds to us will be set forth in a prospectus supplement. The price to the public of such securities and the net proceeds
we expect to receive from such sale will also be set forth in a prospectus supplement.
Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
The
date of this prospectus is , 2020
TABLE
OF CONTENTS
ABOUT
THIS PROSPECTUS
This
prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, or the SEC, using a
“shelf” registration process. Under this shelf registration process, from time to time, we may sell any combination
of the securities described in this prospectus in one or more offerings, up to a total dollar amount of $100,000,000. We have
provided to you in this prospectus a general description of the securities we may offer. Each time we sell securities under this
shelf registration process, we will provide a prospectus supplement that will contain specific information about the terms of
the offering. We may also add, update or change in the prospectus supplement any of the information contained in this prospectus.
To the extent there is a conflict between the information contained in this prospectus and the prospectus supplement, you should
rely on the information in the prospectus supplement; provided that, if any statement in one of these documents is inconsistent
with a statement in another document having a later date—for example, a document incorporated by reference in this prospectus
or any prospectus supplement—the statement in the document having the later date modifies or supersedes the earlier statement.
You should read both this prospectus and any prospectus supplement together with additional information described under the heading
“Where You Can Find More Information.”
Neither
we, nor any agent, underwriter or dealer have authorized anyone to give you any information or to make any representation other
than the information and representations contained in or incorporated by reference into this prospectus or any applicable prospectus
supplement. We and any agent, underwriter or dealer take no responsibility for, and can provide no assurance as to the reliability
of, any other information others may give you. You may not imply from the delivery of this prospectus and any applicable prospectus
supplement, nor from a sale made under this prospectus and any applicable prospectus supplement, that our affairs are unchanged
since the date of this prospectus and any applicable prospectus supplement or that the information contained in any document incorporated
by reference is accurate as of any date other than the date of the document incorporated by reference, regardless of the time
of delivery of this prospectus and any applicable prospectus supplement or any sale of a security. This prospectus and any applicable
prospectus supplement may only be used where it is legal to sell the securities.
THIS
PROSPECTUS MAY NOT BE USED TO OFFER AND SELL SECURITIES UNLESS IT IS ACCOMPANIED BY AN ADDITIONAL PROSPECTUS OR A PROSPECTUS SUPPLEMENT.
In
this prospectus, unless the context otherwise requires, the terms “CohBar,” the “Company,” “we,”
“us,” and “our” refer to CohBar, Inc., a Delaware corporation.
PROSPECTUS
SUMMARY
This
summary highlights information contained in other parts of this prospectus or incorporated by reference in this prospectus from
our Annual Report on Form 10-K for the year ended December 31, 2019, and our other filings with the SEC listed below under the
heading “Incorporation of Information by Reference.” This summary may not contain all the information that you should
consider before investing in securities. You should read the entire prospectus and the information incorporated by reference in
this prospectus carefully, including “Risk Factors” and the financial data and related notes and other information
incorporated by reference, before making an investment decision. See “Forward-Looking Statements.”
Our
Company
CohBar,
Inc. is a clinical stage biotechnology company and a leader in the research and development of mitochondria based therapeutics,
or MBTs, an emerging class of drugs with the potential to treat a wide range of chronic and age-related diseases, including non-alcoholic
steatohepatitis, or NASH, obesity, cancer, fibrotic diseases including IPF, acute respiratory distress syndrome, or ARDS, including
COVID-19 associated ARDS, type 2 diabetes mellitus, or T2D, and cardiovascular and neurodegenerative diseases.
MBTs
originate from almost two decades of research by our founders, resulting in their discovery of a novel group of mitochondrial-derived
peptides, or MDPs encoded within the mitochondrial genome. Some of these naturally occurring MDPs and their analogs have demonstrated
a range of biological activity and therapeutic potential in research models across multiple diseases associated with aging.
We
are focused on building our organization, enhancing our scientific and management teams and their capabilities, planning and strategy,
raising capital and the research and development of our MDPs. Our research efforts have focused on discovering and evaluating
our MDPs for potential development as MBT drug candidates.
Our
efforts have resulted in the identification of more than 100 previously unidentified peptides encoded within the mitochondrial
genome and generated over 1,000 analogs. Many of these MDPs and their analogs have demonstrated various degrees of biological
activity in cell based and/or animal models relevant to a wide range of diseases, such as NASH, obesity, cancer, fibrotic diseases
including IPF, T2D and cardiovascular and neurodegenerative diseases.
The
Securities We May Offer
With
this prospectus, we may offer common stock, preferred stock, debt securities, warrants to purchase our common stock, preferred
stock or debt securities, subscription rights to purchase our common stock, preferred stock or debt securities, and/or units consisting
of some or all of these securities in any combination. The aggregate offering price of securities that we offer with this prospectus
will not exceed $100,000,000. Each time we offer securities with this prospectus, we will provide offerees with a prospectus supplement
that will contain the specific terms of the securities being offered. The following is a summary of the securities we may offer
with this prospectus.
Common
Stock
We
may offer shares of our common stock, par value $0.001 per share.
Preferred
Stock
We
may offer shares of our preferred stock, par value $0.001 per share, in one or more series. Our board of directors or a committee
designated by the board will determine the dividend, voting, conversion and other rights of the series of shares of preferred
stock being offered. Each series of preferred stock will be more fully described in the particular prospectus supplement that
will accompany this prospectus, including redemption provisions, rights in the event of our liquidation, dissolution or the winding
up, voting rights and rights to convert into common stock.
Debt
Securities
We
may offer general obligations, which may be secured or unsecured, senior or subordinated and convertible into shares of our common
stock or preferred stock. In this prospectus, we refer to the senior debt securities and the subordinated debt securities together
as the “debt securities.” Our board of directors will determine the terms of each series of debt securities being
offered.
We
will issue the debt securities under an indenture between us and a trustee. In this document, we have summarized general features
of the debt securities from the indenture. We encourage you to read the indenture, which is an exhibit to the registration statement
of which this prospectus is a part.
Warrants
We
may offer warrants for the purchase of debt securities, shares of preferred stock or shares of common stock. We may issue warrants
independently or together with other securities. Our board of directors will determine the terms of the warrants.
Subscription
Rights
We
may offer subscription rights for the purchase of common stock, preferred stock or debt securities. We may issue subscription
rights independently or together with other securities. Our board of directors will determine the terms of the subscription rights.
Units
We
may offer units consisting of some or all of the securities described above, in any combination, including common stock, preferred
stock, warrants and/or debt securities. The terms of these units will be set forth in a prospectus supplement. The description
of the terms of these units in the related prospectus supplement will not be complete. You should refer to the applicable form
of unit and unit agreement for complete information with respect to these units.
*
* *
Our
Company was formed as a Delaware limited liability company on October 19, 2007. We converted to a Delaware corporation under the
provisions of the Delaware Limited Liability Company Act and the Delaware General Corporation Law on September 16, 2009. Our principal
executive offices are located at 1455 Adams Dr., Suite 2050, Menlo Park, CA 94025. Our telephone number is (650) 446-7888. We
maintain a website at www.cohbar.com. The information contained on, connected to or that can be accessed via our website is not
a part of, and is not incorporated into, this prospectus and the inclusion of our website address in this prospectus is an inactive
textual reference only. We have no subsidiaries.
RISK
FACTORS
An
investment in our securities involves a high degree of risk. The prospectus supplement applicable to each offering of securities
will contain a discussion of the risks applicable to an investment in our securities. Prior to making a decision about investing
in our securities, you should carefully consider the specific factors discussed under the heading “Risk Factors” in
the applicable prospectus supplement, together with all of the other information contained or incorporated by reference in the
prospectus supplement or appearing or incorporated by reference in this prospectus. You should also consider the risks, uncertainties
and assumptions discussed under Part II, Item 1A, “Risk Factors,” in our Quarterly Report on Form 10-Q for the quarter
ended June 30, 2020, which is incorporated herein by reference, and may be amended, supplemented or superseded from time to time
by other reports we file with the SEC in the future. The risks and uncertainties we have described are not the only ones we face.
Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our operations.
FORWARD-LOOKING
STATEMENTS
This
prospectus and documents incorporated herein by reference contain “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties.
We caution readers that any forward-looking statement is not a guarantee of future performance and that actual results could differ
materially from those contained in the forward-looking statement. These statements are based on current expectations of future
events.
Such
statements include, but are not limited to, statements regarding expectations and intentions, costs and expenses, outcome of contingencies,
financial condition, results of operations, liquidity, cost savings, objectives of management, debt financing, our future results
of operations and financial position, business strategies, market size, potential growth opportunities, clinical development activities,
efficacy and safety profile of our product candidates, timing and results of our nonclinical studies and clinical trials, the
receipt and timing of potential regulatory designations, our ability to maintain and recognize the benefits of certain designations
received by product candidates, the achievement of clinical and commercial milestones, the advancement of our technologies and
our proprietary product candidates, the successful achievement of the goals of our collaborations, the advancement of the product
candidates that are the subjects of these collaborations, the approvals and commercialization of product candidates and other
statements that are not historical facts. You can find many of these statements by looking for words like “believes,”
“expects,” “anticipates,” “estimates,” “may,” “might,” “should,”
“will,” “could,” “plan,” “intend,” “project,” “seek” or
similar expressions in this prospectus, in documents incorporated by reference into this prospectus or any free writing prospectus.
We intend that such forward-looking statements be subject to the safe harbors created thereby.
These
forward-looking statements are based on the current beliefs and expectations of our management and are subject to significant
risks and uncertainties. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results
may differ materially from current expectations and projections. Factors that might cause such a difference include those discussed
in Part II, Item 1A, “Risk Factors,” in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, as
well as those discussed in this prospectus, the documents incorporated by reference into this prospectus and any free writing
prospectus. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date
of this prospectus or, in the case of documents referred to or incorporated by reference, the date of those documents.
All
subsequent written or oral forward-looking statements attributable to us or any person acting on our behalf are expressly qualified
in their entirety by the cautionary statements contained or referred to in this section. We do not undertake any obligation to
release publicly any revisions to these forward-looking statements to reflect events or circumstances after the date of this prospectus
or to reflect the occurrence of unanticipated events, except as may be required under applicable U.S. securities law. If we do
update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect
to those or other forward-looking statements.
WHERE
YOU CAN FIND MORE INFORMATION
We
have filed with the SEC a registration statement on Form S-3 under the Securities Act with respect to the securities offered hereby.
This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in
the registration statement, the exhibits filed therewith or the documents incorporated by reference therein. For further information
about us and the securities offered hereby, reference is made to the registration statement, the exhibits filed therewith and
the documents incorporated by reference therein. Statements contained in this prospectus regarding the contents of any contract
or any other document that is filed as an exhibit to the registration statement are not necessarily complete, and in each instance,
we refer you to the copy of such contract or other document filed as an exhibit to the registration statement.
We
are subject to the informational requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act and are
required to file annual, quarterly and other reports, proxy statements and other information with the SEC. The SEC maintains an
Internet site (http://www.sec.gov) that contains reports, proxy and information statements, and various other information about
us. You may also inspect the documents described herein at our principal executive offices, 1455 Adams Drive, Suite 2050, Menlo
Park, California 94025, during normal business hours.
Information
about us is also available at our website at www.cohbar.com. However, the information on our website is not a part of this prospectus
and is not incorporated by reference into this prospectus.
INCORPORATION
OF INFORMATION BY REFERENCE
The
SEC allows us to “incorporate by reference” information that we file with the SEC, which means that we can disclose
important information to you by referring you to those other documents. The information incorporated by reference is an important
part of this prospectus, and information we file later with the SEC will automatically update and supersede this information.
A Current Report (or portion thereof) furnished, but not filed, on Form 8-K shall not be incorporated by reference into this prospectus.
We incorporate by reference the documents listed below and any future filings we make with the SEC under Section 13(a), 13(c),
14, or 15(d) of the Exchange Act prior to the termination of any offering of securities made by this prospectus:
|
●
|
our
Annual Report on Form 10-K
for the fiscal year ended December 31, 2019, filed with the SEC on March 12, 2020, including certain information incorporated
by reference therein from our Definitive Proxy Statement on Schedule 14A for our 2020 annual meeting of stockholders, filed with the SEC on April 29, 2020;
|
|
●
|
our
Quarterly Reports on Form 10-Q for the quarters ended March 31, 2020, filed with the SEC on May 14, 2020,
and June 30, 2020, filed with the SEC on August 13, 2020;
|
|
●
|
our
Current Reports on Form 8-K filed on March 30, 2020, May 13, 2020, May 27, 2020, June 18, 2020 and July 9, 2020;
|
|
●
|
the
description of our common stock contained in our registration statement on Form 8-A filed with the SEC on December 13, 2017 under Section 12 of the Exchange Act, including any amendment or report
filed for the purpose of updating such description; and
|
|
●
|
filings
we make with the SEC pursuant to the Exchange Act after the date of the initial registration statement, of which this prospectus
is a part, and prior to the effectiveness of the registration statement.
|
We
will furnish without charge to you, on written or oral request, a copy of any or all of such documents that has been incorporated
herein by reference (other than exhibits to such documents unless such exhibits are specifically incorporated by reference into
the documents that this prospectus incorporates). Written or oral requests for copies should be directed to CohBar, Inc., Attn:
Corporate Secretary, 1455 Adams Drive, Suite 2050, Menlo Park, California 94025, and our telephone number is (650) 446-7888. See
the section of this prospectus entitled “Where You Can Find More Information” for information concerning how to obtain
copies of materials that we file with the SEC.
Any
statement contained in this prospectus, or in a document, all or a portion of which is incorporated by reference, shall be modified
or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus, any prospectus supplement
or any document incorporated by reference modifies or supersedes such statement. Any such statement so modified or superseded
shall not, except as so modified or superseded, constitute a part of this prospectus.
USE
OF PROCEEDS
We
will retain broad discretion over the use of the net proceeds to us from the sale of our securities under this prospectus. Unless
otherwise provided in the applicable prospectus supplement, we intend to use the net proceeds from the sale of securities under
this prospectus for general corporate purposes, which may include funding research, preclinical and clinical development of our
product candidates, increasing our working capital, reducing indebtedness, acquisitions or investments in businesses, products
or technologies that are complementary to our own and capital expenditures. We will set forth in the applicable prospectus supplement
our intended use for the net proceeds received from the sale of any securities. Pending the application of the net proceeds, we
intend to invest the net proceeds in short-term or long-term, investment-grade, interest-bearing securities.
PLAN
OF DISTRIBUTION
We
may sell the securities covered by this prospectus to one or more underwriters for public offering and sale by them, and may also
sell the securities to investors directly or through agents. We will name any underwriter or agent involved in the offer and sale
of securities in the applicable prospectus supplement. We have reserved the right to sell or exchange securities directly to investors
on our own behalf in jurisdictions where we are authorized to do so. We may distribute the securities from time to time in one
or more transactions:
|
●
|
at
a fixed price or prices, which may be changed;
|
|
●
|
at
market prices prevailing at the time of sale;
|
|
●
|
at
prices related to such prevailing market prices; or
|
|
●
|
at
negotiated prices.
|
We
may directly solicit offers to purchase the securities being offered by this prospectus. We may also designate agents to solicit
offers to purchase the securities from time to time. We will name in a prospectus supplement any agent involved in the offer or
sale of our securities. Unless otherwise indicated in a prospectus supplement, an agent will be acting on a best efforts basis,
and a dealer will purchase securities as a principal for resale at varying prices to be determined by the dealer.
If
we utilize an underwriter in the sale of the securities being offered by this prospectus, we will execute an underwriting agreement
with the underwriter at the time of sale and we will provide the name of any underwriter in the prospectus supplement that the
underwriter will use to make resales of the securities to the public. In connection with the sale of the securities, we, or the
purchasers of securities for whom the underwriter may act as agent, may compensate the underwriter in the form of underwriting
discounts or commissions. The underwriter may sell the securities to or through dealers, and those dealers may receive compensation
in the form of discounts, concessions or commissions from the underwriters or commissions from the purchasers for whom they may
act as agent.
We
will provide in the applicable prospectus supplement any compensation we pay to underwriters, dealers or agents in connection
with the offering of the securities, and any discounts, concessions or commissions allowed by underwriters to participating dealers.
Underwriters, dealers and agents participating in the distribution of the securities may be deemed to be underwriters within the
meaning of the Securities Act of 1933, as amended, or the Securities Act, and any discounts and commissions received by them and
any profit realized by them on resale of the securities may be deemed to be underwriting discounts and commissions. We may enter
into agreements to indemnify underwriters, dealers and agents against civil liabilities, including liabilities under the Securities
Act, and to reimburse them for certain expenses. We may grant underwriters who participate in the distribution of our securities
under this prospectus an option to purchase additional securities to cover any over-allotments in connection with the distribution.
The
securities we offer under this prospectus may or may not be listed through the Nasdaq Capital Market or any other securities exchange.
To facilitate the offering of securities, certain persons participating in the offering may engage in transactions that stabilize,
maintain or otherwise affect the price of the securities. This may include short sales of the securities, which involves the sale
by persons participating in the offering of more securities than we sold to them. In these circumstances, these persons would
cover such short positions by making purchases in the open market or by exercising their option to purchase additional securities.
In addition, these persons may stabilize or maintain the price of the securities by bidding for or purchasing securities in the
open market or by imposing penalty bids, whereby selling concessions allowed to dealers participating in the offering may be reclaimed
if securities sold by them are repurchased in connection with stabilization transactions. The effect of these transactions may
be to stabilize or maintain the market price of the securities at a level above that which might otherwise prevail in the open
market. These transactions may be discontinued at any time.
We
may engage in at the market offerings into an existing trading market in accordance with Rule 415(a)(4) under the Securities Act.
In addition, we may enter into derivative transactions with third parties, or sell securities not covered by this prospectus to
third parties in privately negotiated transactions. If the applicable prospectus supplement indicates, in connection with those
derivatives, the third parties may sell securities covered by this prospectus and the applicable prospectus supplement, including
short sale transactions. If so, the third party may use securities pledged by us or borrowed from us or others to settle those
sales or to close out any related open borrowings of stock, and they may use securities received from us in settlement of those
derivatives to close out any related open borrowings of stock. The third party in these sale transactions will be an underwriter
and will be identified in the applicable prospectus supplement. In addition, we may otherwise loan or pledge securities to a financial
institution or other third party that in turn may sell the securities short using this prospectus. The financial institution or
other third party may transfer its economic short position to investors in our securities or in connection with a concurrent offering
of other securities.
We
will file a prospectus supplement to describe the terms of any offering of our securities covered by this prospectus. The prospectus
supplement will disclose:
|
●
|
the
terms of the offer;
|
|
●
|
the
names of any underwriters, including any managing underwriters, as well as any dealers or agents;
|
|
●
|
the
purchase price of the securities from us;
|
|
●
|
the
net proceeds to us from the sale of the securities;
|
|
●
|
any
delayed delivery arrangements;
|
|
●
|
any
over-allotment or other options under which underwriters, if any, may purchase additional securities from us;
|
|
●
|
any
underwriting discounts, commissions or other items constituting underwriters’ compensation, and any commissions paid
to agents;
|
|
●
|
in
a subscription rights offering, whether we have engaged dealer-managers to facilitate the offering or subscription, including
their name or names and compensation;
|
|
●
|
any
public offering price; and
|
|
●
|
other
facts material to the transaction.
|
We
will bear all or substantially all of the costs, expenses and fees in connection with the registration of our securities under
this prospectus. The underwriters, dealers and agents may engage in transactions with us, or perform services for us, in the ordinary
course of business.
Under
Rule 15c6-1 of the Exchange Act, trades in the secondary market generally are required to settle in two business days, unless
the parties to any such trade expressly agree otherwise or the securities are sold by us to an underwriter in a firm commitment
underwritten offering. The applicable prospectus supplement may provide that the original issue date for your securities may be
more than two scheduled business days after the trade date for your securities. Accordingly, in such a case, if you wish to trade
securities on any date prior to the second business day before the original issue date for your securities, you will be required,
by virtue of the fact that your securities initially are expected to settle in more than two scheduled business days after the
trade date for your securities, to make alternative settlement arrangements to prevent a failed settlement.
DESCRIPTION
OF CAPITAL STOCK
General
Our
authorized capital stock consists of 180,000,000 shares of common stock, $0.001 par value per share, and 5,000,000 shares of undesignated
preferred stock, $0.001 par value per share. The following description summarizes the most important terms of our capital stock.
Because it is only a summary, it does not contain all the information that may be important to you. For a complete description,
you should refer to our Third Amended and Restated Certificate of Incorporation, as amended, or restated certificate of incorporation,
and Amended and Restated Bylaws, or restated bylaws, which are included as exhibits to the registration statement of which this
prospectus forms a part, and to the applicable provisions of Delaware law.
As
of August 20, 2020, there were 45,663,409 shares of our common stock outstanding, and no shares of preferred stock outstanding.
Common
Stock
Dividend
rights
Subject
to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of our common stock are entitled
to receive dividends out of funds legally available if our board of directors, in its discretion, determines to issue dividends
and then only at the times and in the amounts that our board of directors may determine. For more information about our dividend
policy, see “Dividends” in our Annual Report on Form 10-K for the year ended December 31, 2019, which is incorporated
by reference in this prospectus.
Voting
rights
Holders
of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders, provided
that holders of common stock are not entitled to vote on amendments to our certificate of incorporation related solely to the
terms of one or more outstanding series of preferred stock if the holders of such series are entitled to vote thereon, unless
required by law. We have not provided for cumulative voting for the election of directors in our restated certificate of incorporation,
which means that holders of a majority of the shares of our common stock are able to elect all of our directors.
No
preemptive or similar rights
Our
common stock is not entitled to preemptive rights, and is not subject to conversion, redemption or sinking fund provisions.
Right
to receive liquidation distributions
Upon
our liquidation, dissolution or winding-up, the assets legally available for distribution to our stockholders would be distributable
ratably among the holders of our common stock and any participating preferred stock outstanding at that time, subject to prior
satisfaction of all outstanding debt and liabilities and the preferential rights of and the payment of liquidation preferences,
if any, on any outstanding shares of preferred stock.
Preferred
Stock
Our
board of directors is authorized, subject to limitations prescribed by Delaware law, to issue preferred stock in one or more series,
to establish from time to time the number of shares to be included in each series and to fix the designation, powers, preferences
and rights of the shares of each series and any of their qualifications, limitations or restrictions, in each case without further
vote or action by our stockholders. Our board of directors can also increase or decrease the number of shares of any series of
preferred stock, but not below the number of shares of that series then outstanding, without any further vote or action by our
stockholders. Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could
adversely affect the voting power or other rights of the holders of our common stock. The issuance of preferred stock, while providing
flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect
of delaying, deferring or preventing a change in control of our company and might adversely affect the market price of our common
stock and the voting and other rights of the holders of our common stock. We have no current plan to issue any shares of preferred
stock.
Warrants
As
of August 20, 2020, we had outstanding warrants to purchase an aggregate of 4,887,223 shares of our common stock at a weighted
average exercise price of $1.99 per share.
Anti-Takeover
Provisions
The
provisions of Delaware General Corporation Law, or DGCL, our restated certificate of incorporation and our restated bylaws, could
have the effect of delaying, deferring or discouraging another person from acquiring control of our company. These provisions,
which are summarized below, may have the effect of discouraging takeover bids. They are also designed, in part, to encourage persons
seeking to acquire control of us to negotiate first with our board of directors. We believe that the benefits of increased protection
of our potential ability to negotiate with an unfriendly or unsolicited acquirer outweigh the disadvantages of discouraging a
proposal to acquire us because negotiation of these proposals could result in an improvement of their terms.
Delaware
Law
We
are subject to the provisions of Section 203 of the DGCL regulating corporate takeovers. In general, Section 203 prohibits a publicly
held Delaware corporation from engaging in a “business combination” with an “interested stockholder” for
a period of three years following the date on which the person became an interested stockholder unless:
|
●
|
prior
to the date of the transaction, the board of directors of the corporation approved either the business combination or the
transaction which resulted in the stockholder becoming an interested stockholder;
|
|
●
|
the
interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced,
excluding for purposes of determining the voting stock outstanding, but not the outstanding voting stock owned by the interested
stockholder, (i) shares owned by persons who are directors and also officers and (ii) shares owned by employee stock plans
in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will
be tendered in a tender or exchange offer; or
|
|
●
|
at
or subsequent to the date of the transaction, the business combination is approved by the board of directors of the corporation
and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at
least 66.67% of the outstanding voting stock that is not owned by the interested stockholder.
|
Generally,
a business combination includes a merger, asset or stock sale, or other transaction or series of transactions together resulting
in a financial benefit to the interested stockholder. An interested stockholder is a person who, together with affiliates and
associates, owns or, within three years prior to the determination of interested stockholder status, did own 15% or more of a
corporation’s outstanding voting stock. We expect the existence of this provision to have an anti-takeover effect with respect
to transactions our board of directors does not approve in advance. We also anticipate that Section 203 may also discourage attempts
that might result in a premium over the market price for the shares of common stock held by stockholders.
Restated
Certificate of Incorporation and Restated Bylaw Provisions
Our
restated certificate of incorporation and our restated bylaws include a number of provisions that could deter hostile takeovers
or delay or prevent changes in control of our company, including the following:
|
●
|
Board
of Directors vacancies. Our restated certificate of incorporation and restated bylaws authorize only our board of
directors to fill vacant directorships, including newly created seats. In addition, the number of directors constituting our
board of directors is permitted to be set only by a resolution adopted by a majority vote of our entire board of directors.
These provisions prevent a stockholder from increasing the size of our board of directors and then gaining control of our
board of directors by filling the resulting vacancies with its own nominees. This makes it more difficult to change the composition
of our board of directors but promotes continuity of management.
|
|
●
|
Stockholder
action. Our restated certificate of incorporation provides that our stockholders may not take action by written consent,
but may only take action at annual or special meetings of our stockholders. As a result, a holder controlling a majority of
our capital stock would not be able to amend our restated bylaws or remove directors without holding a meeting of our stockholders
called in accordance with our restated bylaws.
|
|
●
|
Advance
notice requirements for stockholder proposals and director nominations. Our restated bylaws provide advance notice
procedures for stockholders seeking to bring business before our annual meeting of stockholders or to nominate candidates
for election as directors at our annual meeting of stockholders. Our restated bylaws also specify certain requirements regarding
the form and content of a stockholder’s notice. These provisions might preclude our stockholders from bringing matters
before our annual meeting of stockholders or from making nominations for directors at our annual meeting of stockholders if
the proper procedures are not followed. We expect that these provisions might also discourage or deter a potential acquirer
from conducting a solicitation of proxies to elect the acquirer’s own slate of directors or otherwise attempting to
obtain control of our company.
|
|
●
|
No
cumulative voting. The DGCL provides that stockholders are not entitled to the right to cumulate votes in the election
of directors unless a corporation’s certificate of incorporation provides otherwise. Our restated certificate of incorporation
and restated bylaws do not provide for cumulative voting.
|
|
●
|
Issuance
of undesignated preferred stock. Our board of directors has the authority, without further action by the stockholders,
to issue up to 5,000,000 shares of undesignated preferred stock with rights and preferences, including voting rights, designated
from time to time by our board of directors. The existence of authorized but unissued shares of preferred stock enables our
board of directors to render more difficult or to discourage an attempt to obtain control of us by merger, tender offer, proxy
contest or other means.
|
|
●
|
Choice
of forum. Our restated certificate of incorporation provides that, to the fullest extent permitted by law, the Court
of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf;
any action asserting a breach of fiduciary duty; any action asserting a claim against us arising pursuant to the DGCL, our
restated certificate of incorporation or our restated bylaws; or any action asserting a claim against us that is governed
by the internal affairs doctrine. The provision does not apply to suits brought to enforce a duty or liability created by
the Exchange Act.
|
Transfer
Agent and Registrar
The
transfer agent and registrar for our common stock is AST Trust Company (Canada).
Exchange
Listing
Our
common stock is listed on the Nasdaq Capital Market under the symbol “CWBR.”
DESCRIPTION
OF DEBT SECURITIES
General
We
will issue the debt securities offered by this prospectus and any accompanying prospectus supplement under an indenture to be
entered into between us and the trustee identified in the applicable prospectus supplement. The terms of the debt securities will
include those stated in the indenture and those made part of the indenture by reference to the Trust Indenture Act of 1939, as
in effect on the date of the indenture. We have filed a copy of the form of indenture as an exhibit to the registration statement
in which this prospectus is included. The indenture will be subject to and governed by the terms of the Trust Indenture Act of
1939.
We
may offer under this prospectus up to an aggregate principal amount of $100,000,000 in debt securities, or if debt securities
are issued at a discount, or in a foreign currency, foreign currency units or composite currency, the principal amount as may
be sold for an aggregate public offering price of up to $100,000,000. Unless otherwise specified in the applicable prospectus
supplement, the debt securities will represent our direct, unsecured obligations and will rank equally with all of our other unsecured
indebtedness.
We
may issue the debt securities in one or more series with the same or various maturities, at par, at a premium, or at a discount.
We will describe the particular terms of each series of debt securities in a prospectus supplement relating to that series, which
we will file with the SEC. The prospectus supplement relating to the particular series of debt securities being offered will specify
the particular amounts, prices and terms of those debt securities. These terms may include:
|
●
|
the
title of the series;
|
|
●
|
the
aggregate principal amount, and, if a series, the total amount authorized and the total amount outstanding;
|
|
●
|
the
issue price or prices, expressed as a percentage of the aggregate principal amount of the debt securities;
|
|
●
|
any
limit on the aggregate principal amount;
|
|
●
|
the
date or dates on which principal is payable;
|
|
●
|
the
interest rate or rates (which may be fixed or variable) or, if applicable, the method used to determine such rate or rates;
|
|
●
|
the
date or dates from which interest, if any, will be payable and any regular record date for the interest payable;
|
|
●
|
the
place or places where principal and, if applicable, premium and interest, is payable;
|
|
●
|
the
terms and conditions upon which we may, or the holders may require us to, redeem or repurchase the debt securities;
|
|
●
|
the
denominations in which such debt securities may be issuable, if other than denominations of $1,000 or any integral multiple
of that number;
|
|
●
|
whether
the debt securities are to be issuable in the form of certificated securities (as described below) or global securities (as
described below);
|
|
●
|
the
portion of principal amount that will be payable upon declaration of acceleration of the maturity date if other than the principal
amount of the debt securities;
|
|
●
|
the
currency of denomination;
|
|
●
|
the
designation of the currency, currencies or currency units in which payment of principal and, if applicable, premium and interest,
will be made;
|
|
●
|
if
payments of principal and, if applicable, premium or interest, on the debt securities are to be made in one or more currencies
or currency units other than the currency of denomination, the manner in which the exchange rate with respect to such payments
will be determined;
|
|
●
|
if
amounts of principal and, if applicable, premium and interest may be determined by reference to an index based on a currency
or currencies or by reference to a commodity, commodity index, stock exchange index or financial index, then the manner in
which such amounts will be determined;
|
|
●
|
the
provisions, if any, relating to any collateral provided for such debt securities;
|
|
●
|
any
addition to or change in the covenants and/or the acceleration provisions described in this prospectus or in the indenture;
|
|
●
|
any
events of default, if not otherwise described below under “Events of Default”;
|
|
●
|
the
terms and conditions, if any, for conversion into or exchange for shares of our common stock or preferred stock;
|
|
●
|
any
depositaries, interest rate calculation agents, exchange rate calculation agents or other agents; and
|
|
●
|
the
terms and conditions, if any, upon which the debt securities shall be subordinated in right of payment to our other indebtedness.
|
We
may issue discount debt securities that provide for an amount less than the stated principal amount to be due and payable upon
acceleration of the maturity of such debt securities in accordance with the terms of the indenture. We may also issue debt securities
in bearer form, with or without coupons. If we issue discount debt securities or debt securities in bearer form, we will describe
material U.S. federal income tax considerations and other material special considerations which apply to these debt securities
in the applicable prospectus supplement.
We
may issue debt securities denominated in or payable in a foreign currency or currencies or a foreign currency unit or units. If
we do, we will describe the restrictions, elections, and general tax considerations relating to the debt securities and the foreign
currency or currencies or foreign currency unit or units in the applicable prospectus supplement.
Debt
securities offered under this prospectus and any prospectus supplement will be subordinated in right of payment to certain of
our outstanding senior indebtedness. In addition, we will seek the consent of the holders of any such senior indebtedness prior
to issuing any debt securities under this prospectus to the extent required by the agreements evidencing such senior indebtedness.
Registrar
and Paying Agent
The
debt securities may be presented for registration of transfer or for exchange at the corporate trust office of the security registrar
or at any other office or agency that we maintain for those purposes. In addition, the debt securities may be presented for payment
of principal, interest and any premium at the office of the paying agent or at any office or agency that we maintain for those
purposes.
Conversion
or Exchange Rights
Debt
securities may be convertible into or exchangeable for shares of our common stock. The terms and conditions of conversion or exchange
will be stated in the applicable prospectus supplement. The terms will include, among others, the following:
|
●
|
the
conversion or exchange price;
|
|
●
|
the
conversion or exchange period;
|
|
●
|
provisions
regarding the convertibility or exchangeability of the debt securities, including who may convert or exchange;
|
|
●
|
events
requiring adjustment to the conversion or exchange price;
|
|
●
|
provisions
affecting conversion or exchange in the event of our redemption of the debt securities; and
|
|
●
|
any
anti-dilution provisions, if applicable.
|
Registered
Global Securities
If
we decide to issue debt securities in the form of one or more global securities, then we will register the global securities in
the name of the depositary for the global securities or the nominee of the depositary, and the global securities will be delivered
by the trustee to the depositary for credit to the accounts of the holders of beneficial interests in the debt securities.
The
prospectus supplement will describe the specific terms of the depositary arrangement for debt securities of a series that are
issued in global form. None of us, the trustee, any payment agent or the security registrar will have any responsibility or liability
for any aspect of the records relating to or payments made on account of beneficial ownership interests in a global debt security
or for maintaining, supervising or reviewing any records relating to these beneficial ownership interests.
No
Protection in the Event of Change of Control
The
indenture does not have any covenants or other provisions providing for a put or increased interest or otherwise that would afford
holders of our debt securities additional protection in the event of a recapitalization transaction, a change of control or a
highly leveraged transaction. If we offer any covenants or provisions of this type with respect to any debt securities covered
by this prospectus, we will describe them in the applicable prospectus supplement.
Covenants
Unless
otherwise indicated in this prospectus or the applicable prospectus supplement, our debt securities will not have the benefit
of any covenants that limit or restrict our business or operations, the pledging of our assets or the incurrence by us of indebtedness.
We will describe in the applicable prospectus supplement any material covenants in respect of a series of debt securities.
Merger,
Consolidation or Sale of Assets
The
form of indenture provides that we will not consolidate with or merge into any other person or convey, transfer, sell or lease
our properties and assets substantially as an entirety to any person, unless:
|
●
|
we
are the surviving person of such merger or consolidation, or if we are not the surviving person, the person formed by the
consolidation or into or with which we are merged or the person to which our properties and assets are conveyed, transferred,
sold or leased, is a corporation organized and existing under the laws of the U.S., any state or the District of Columbia
or a corporation or comparable legal entity organized under the laws of a foreign jurisdiction and has expressly assumed all
of our obligations, including the payment of the principal of and, premium, if any, and interest on the debt securities and
the performance of the other covenants under the indenture; and
|
|
●
|
immediately
before and immediately after giving effect to the transaction on a pro forma basis, no event of default, and no event which,
after notice or lapse of time or both, would become an event of default, has occurred and is continuing under the indenture.
|
Events
of Default
Unless
otherwise specified in the applicable prospectus supplement, the following events will be events of default under the indenture
with respect to debt securities of any series:
|
●
|
we
fail to pay any principal or premium, if any, when it becomes due;
|
|
●
|
we
fail to pay any interest within 30 days after it becomes due;
|
|
●
|
we
fail to observe or perform any other covenant in the debt securities or the indenture for 90 days after written notice specifying
the failure from the trustee or the holders of not less than 25% in aggregate principal amount of the outstanding debt securities
of that series; and
|
|
●
|
certain
events involving bankruptcy, insolvency or reorganization of us or any of our significant subsidiaries.
|
The
trustee may withhold notice to the holders of the debt securities of any series of any default, except in payment of principal
of or premium, if any, or interest on the debt securities of a series, if the trustee considers it to be in the best interest
of the holders of the debt securities of that series to do so.
If
an event of default (other than an event of default resulting from certain events of bankruptcy, insolvency or reorganization)
occurs, and is continuing, then the trustee or the holders of not less than 25% in aggregate principal amount of the outstanding
debt securities of any series may accelerate the maturity of the debt securities. If this happens, the entire principal amount,
plus the premium, if any, of all the outstanding debt securities of the affected series plus accrued interest to the date of acceleration
will be immediately due and payable. At any time after the acceleration, but before a judgment or decree based on such acceleration
is obtained by the trustee, the holders of a majority in aggregate principal amount of outstanding debt securities of such series
may rescind and annul such acceleration if:
|
●
|
all
events of default (other than nonpayment of accelerated principal, premium or interest) have been cured or waived;
|
|
●
|
all
lawful interest on overdue interest and overdue principal has been paid; and
|
|
●
|
the
rescission would not conflict with any judgment or decree.
|
In
addition, if the acceleration occurs at any time when we have outstanding indebtedness that is senior to the debt securities,
the payment of the principal amount of outstanding debt securities may be subordinated in right of payment to the prior payment
of any amounts due under the senior indebtedness, in which case the holders of debt securities will be entitled to payment under
the terms prescribed in the instruments evidencing the senior indebtedness and the indenture.
If
an event of default resulting from certain events of bankruptcy, insolvency or reorganization occurs, the principal, premium and
interest amount with respect to all of the debt securities of any series will be due and payable immediately without any declaration
or other act on the part of the trustee or the holders of the debt securities of that series.
The
holders of a majority in principal amount of the outstanding debt securities of a series will have the right to waive any existing
default or compliance with any provision of the indenture or the debt securities of that series and to direct the time, method
and place of conducting any proceeding for any remedy available to the trustee, subject to certain limitations specified in the
indenture.
No
holder of any debt security of a series will have any right to institute any proceeding with respect to the indenture or for any
remedy under the indenture, unless:
|
●
|
the
holder gives to the trustee written notice of a continuing event of default;
|
|
●
|
the
holders of at least 25% in aggregate principal amount of the outstanding debt securities of the affected series make a written
request and offer reasonable indemnity to the trustee to institute a proceeding as trustee;
|
|
●
|
the
trustee fails to institute a proceeding within 60 days after such request; and
|
|
●
|
the
holders of a majority in aggregate principal amount of the outstanding debt securities of the affected series do not give
the trustee a direction inconsistent with such request during such 60-day period.
|
These
limitations do not, however, apply to a suit instituted for payment on debt securities of any series on or after the due dates
expressed in the debt securities.
We
will periodically deliver certificates to the trustee regarding our compliance with our obligations under the indenture.
Modification
and Waiver
From
time to time, we and the trustee may, without the consent of holders of the debt securities of one or more series, amend the indenture
or the debt securities of one or more series, or supplement the indenture, for certain specified purposes, including:
|
●
|
to
provide that the surviving entity following a change of control permitted under the indenture will assume all of our obligations
under the indenture and debt securities;
|
|
●
|
to
provide for certificated debt securities in addition to uncertificated debt securities;
|
|
●
|
to
comply with any requirements of the SEC under the Trust Indenture Act of 1939;
|
|
●
|
to
provide for the issuance of and establish the form and terms and conditions of debt securities of any series as permitted
by the indenture;
|
|
●
|
to
cure any ambiguity, defect or inconsistency, or make any other change that does not materially and adversely affect the rights
of any holder; and
|
|
●
|
to
appoint a successor trustee under the indenture with respect to one or more series.
|
From
time to time we and the trustee may, with the consent of holders of at least a majority in principal amount of an outstanding
series of debt securities, amend or supplement the indenture or the debt securities series, or waive compliance in a particular
instance by us with any provision of the indenture or the debt securities. We may not, however, without the consent of each holder
affected by such action, modify or supplement the indenture or the debt securities or waive compliance with any provision of the
indenture or the debt securities in order to:
|
●
|
reduce
the amount of debt securities whose holders must consent to an amendment, supplement, or waiver to the indenture or such debt
security;
|
|
●
|
reduce
the rate of or change the time for payment of interest or reduce the amount of or postpone the date for payment of sinking
fund or analogous obligations;
|
|
●
|
reduce
the principal of or change the stated maturity of the debt securities;
|
|
●
|
make
any debt security payable in money other than that stated in the debt security;
|
|
●
|
change
the amount or time of any payment required or reduce the premium payable upon any redemption, or change the time before which
no such redemption may be made;
|
|
●
|
waive
a default in the payment of the principal of, premium, if any, or interest on the debt securities or a redemption payment;
|
|
●
|
waive
a redemption payment with respect to any debt securities or change any provision with respect to redemption of debt securities;
or
|
|
●
|
take
any other action otherwise prohibited by the indenture to be taken without the consent of each holder affected by the action.
|
Defeasance
of Debt Securities and Certain Covenants in Certain Circumstances
The
indenture permits us, at any time, to elect to discharge our obligations with respect to one or more series of debt securities
by following certain procedures described in the indenture. These procedures will allow us either:
|
●
|
to defease and be discharged from any and all of our obligations with respect to any debt securities except for the following
obligations (which discharge is referred to as “legal defeasance”):
|
|
1.
|
to register the transfer or exchange of such debt securities;
|
|
2.
|
to replace temporary or mutilated, destroyed, lost or stolen debt securities;
|
|
3.
|
to compensate and indemnify the trustee; or
|
|
4.
|
to maintain an office or agency in respect of the debt securities and to hold monies for payment in trust; or
|
|
●
|
to be released from our obligations with respect to the
debt securities under certain covenants contained in the indenture, as well as any additional covenants which may be contained
in the applicable supplemental indenture (which release is referred to as “covenant defeasance”).
|
In
order to exercise either defeasance option, we must irrevocably deposit with the trustee or other qualifying trustee, in trust
for that purpose:
|
●
|
money;
|
|
●
|
U.S.
Government Obligations (as described below) or Foreign Government Obligations (as described below) that through the scheduled
payment of principal and interest in accordance with their terms will provide money; or
|
|
●
|
a
combination of money and/or U.S. Government Obligations and/or Foreign Government Obligations sufficient in the written opinion
of a nationally-recognized firm of independent accountants to provide money;
|
that,
in each case specified above, provides a sufficient amount to pay the principal of, premium, if any, and interest, if any, on
the debt securities of the series, on the scheduled due dates or on a selected date of redemption in accordance with the terms
of the indenture.
In
addition, defeasance may be effected only if, among other things:
|
●
|
in
the case of either legal or covenant defeasance, we deliver to the trustee an opinion of counsel, as specified in the indenture,
stating that as a result of the defeasance neither the trust nor the trustee will be required to register as an investment
company under the Investment Company Act of 1940;
|
|
●
|
in
the case of legal defeasance, we deliver to the trustee an opinion of counsel stating that we have received from, or there
has been published by, the Internal Revenue Service a ruling to the effect that, or there has been a change in any applicable
federal income tax law with the effect that (and the opinion shall confirm that), the holders of outstanding debt securities
will not recognize income, gain or loss for U.S. federal income tax purposes solely as a result of such legal defeasance and
will be subject to U.S. federal income tax on the same amounts, in the same manner, including as a result of prepayment, and
at the same times as would have been the case if legal defeasance had not occurred;
|
|
●
|
in
the case of covenant defeasance, we deliver to the trustee an opinion of counsel to the effect that the holders of the outstanding
debt securities will not recognize income, gain or loss for U.S. federal income tax purposes as a result of covenant defeasance
and will be subject to U.S. federal income tax on the same amounts, in the same manner and at the same times as would have
been the case if covenant defeasance had not occurred; and
|
|
●
|
certain
other conditions described in the indenture are satisfied.
|
If
we fail to comply with our remaining obligations under the indenture and applicable supplemental indenture after a covenant defeasance
of the indenture and applicable supplemental indenture, and the debt securities are declared due and payable because of the occurrence
of any undefeased event of default, the amount of money and/or U.S. Government Obligations and/or Foreign Government Obligations
on deposit with the trustee could be insufficient to pay amounts due under the debt securities of the affected series at the time
of acceleration. We will, however, remain liable in respect of these payments.
The
term “U.S. Government Obligations” as used in the above discussion means securities that are direct obligations of
or non-callable obligations guaranteed by the United States of America for the payment of which obligation or guarantee the full
faith and credit of the United States of America is pledged.
The
term “Foreign Government Obligations” as used in the above discussion means, with respect to debt securities of any
series that are denominated in a currency other than U.S. dollars, (1) direct obligations of the government that issued or caused
to be issued such currency for the payment of which obligations its full faith and credit is pledged or (2) obligations of a person
controlled or supervised by or acting as an agent or instrumentality of such government the timely payment of which is unconditionally
guaranteed as a full faith and credit obligation by that government, which in either case under clauses (1) or (2), are not callable
or redeemable at the option of the issuer.
Regarding
the Trustee
We
will identify the trustee with respect to any series of debt securities in the prospectus supplement relating to the applicable
debt securities. You should note that if the trustee becomes a creditor of ours, the indenture and the Trust Indenture Act of
1939 limit the rights of the trustee to obtain payment of claims in certain cases, or to realize on certain property received
in respect of any such claim, as security or otherwise. The trustee and its affiliates may engage in, and will be permitted to
continue to engage in, other transactions with us and our affiliates. If, however, the trustee acquires any “conflicting
interest” within the meaning of the Trust Indenture Act of 1939, it must eliminate such conflict or resign.
The
holders of a majority in principal amount of the then outstanding debt securities of any series may direct the time, method and
place of conducting any proceeding for exercising any remedy available to the trustee. If an event of default occurs and is continuing,
the trustee, in the exercise of its rights and powers, must use the degree of care and skill of a prudent person in the conduct
of his or her own affairs. Subject to that provision, the trustee will be under no obligation to exercise any of its rights or
powers under the indenture at the request of any of the holders of the debt securities, unless they have offered to the trustee
reasonable indemnity or security.
No
Individual Liability of Incorporators, Stockholders, Officers or Directors
Each
indenture provides that no incorporator and no past, present or future stockholder, officer or director of our company or any
successor corporation in those capacities will have any individual liability for any of our obligations, covenants or agreements
under the debt securities or such indenture.
Governing
Law
The
indentures and the debt securities will be governed by, and construed in accordance with, the laws of the State of New York.
DESCRIPTION
OF WARRANTS
General
We
may issue warrants for the purchase of our debt securities, preferred stock, common stock or any combination thereof. Warrants
may be issued independently or together with our debt securities, preferred stock or common stock and may be attached to or separate
from any offered securities. Each series of warrants will be issued under a separate warrant agreement to be entered into between
us and a bank or trust company, as warrant agent. The warrant agent will act solely as our agent in connection with the warrants.
The warrant agent will not have any obligation or relationship of agency or trust for or with any holders or beneficial owners
of warrants. This summary of certain provisions of the warrants is not complete. For the terms of a particular series of warrants,
you should refer to the prospectus supplement for that series of warrants and the warrant agreement for that particular series.
Debt
Warrants
The
prospectus supplement relating to a particular issue of warrants to purchase debt securities will describe the terms of the debt
warrants, including the following:
|
●
|
the
title of the debt warrants;
|
|
●
|
the
offering price for the debt warrants, if any;
|
|
●
|
the
aggregate number of the debt warrants;
|
|
●
|
the
designation and terms of the debt securities, including any conversion rights, purchasable upon exercise of the debt warrants;
|
|
●
|
if
applicable, the date from and after which the debt warrants and any debt securities issued with them will be separately transferable;
|
|
●
|
the
principal amount of debt securities that may be purchased upon exercise of a debt warrant and the exercise price for the warrants,
which may be payable in cash, securities or other property;
|
|
●
|
the
dates on which the right to exercise the debt warrants will commence and expire;
|
|
●
|
if
applicable, the minimum or maximum amount of the debt warrants that may be exercised at any one time;
|
|
●
|
whether
the debt warrants represented by the debt warrant certificates or debt securities that may be issued upon exercise of the
debt warrants will be issued in registered or bearer form;
|
|
●
|
information
with respect to book-entry procedures, if any;
|
|
●
|
the
currency or currency units in which the offering price, if any, and the exercise price are payable;
|
|
●
|
if
applicable, a discussion of material U.S. federal income tax considerations;
|
|
●
|
the
antidilution provisions of the debt warrants, if any;
|
|
●
|
the
redemption or call provisions, if any, applicable to the debt warrants;
|
|
●
|
any
provisions with respect to the holder’s right to require us to repurchase the debt warrants upon a change in control
or similar event; and
|
|
●
|
any
additional terms of the debt warrants, including procedures and limitations relating to the exchange, exercise, and settlement
of the debt warrants.
|
Debt
warrant certificates will be exchangeable for new debt warrant certificates of different denominations. Debt warrants may be exercised
at the corporate trust office of the warrant agent or any other office indicated in the prospectus supplement. Prior to the exercise
of their debt warrants, holders of debt warrants will not have any of the rights of holders of the debt securities purchasable
upon exercise and will not be entitled to payment of principal or any premium, if any, or interest on the debt securities purchasable
upon exercise.
Equity
Warrants
The
prospectus supplement relating to a particular series of warrants to purchase our common stock or preferred stock will describe
the terms of the warrants, including the following:
|
●
|
the
title of the warrants;
|
|
●
|
the
offering price for the warrants, if any;
|
|
●
|
the
aggregate number of warrants;
|
|
●
|
the
designation and terms of the common stock or preferred stock that may be purchased upon exercise of the warrants;
|
|
●
|
if
applicable, the designation and terms of the securities with which the warrants are issued and the number of warrants issued
with each security;
|
|
●
|
if
applicable, the date from and after which the warrants and any securities issued with the warrants will be separately transferable;
|
|
●
|
the
number of shares of common stock or preferred stock that may be purchased upon exercise of a warrant and the exercise price
for the warrants;
|
|
●
|
the
dates on which the right to exercise the warrants shall commence and expire;
|
|
●
|
if
applicable, the minimum or maximum amount of the warrants that may be exercised at any one time;
|
|
●
|
the
currency or currency units in which the offering price, if any, and the exercise price are payable;
|
|
●
|
if
applicable, a discussion of material U.S. federal income tax considerations;
|
|
●
|
the
antidilution provisions of the warrants, if any;
|
|
●
|
the
redemption or call provisions, if any, applicable to the warrants;
|
|
●
|
any
provisions with respect to a holder’s right to require us to repurchase the warrants upon a change in control or similar
event; and
|
|
●
|
any
additional terms of the warrants, including procedures and limitations relating to the exchange, exercise and settlement of
the warrants.
|
Holders
of equity warrants will not be entitled:
|
●
|
to
vote, consent, or receive dividends;
|
|
●
|
receive
notice as stockholders with respect to any meeting of stockholders for the election of our directors or any other matter;
or
|
|
●
|
exercise
any rights as stockholders.
|
DESCRIPTION
OF SUBSCRIPTION RIGHTS
We
may issue subscription rights to purchase our common stock, preferred stock or debt securities. These subscription rights may
be offered independently or together with any other security offered hereby and may or may not be transferable by the stockholder
receiving the subscription rights in such offering. In connection with any offering of subscription rights, we may enter into
a standby arrangement with one or more underwriters or other purchasers pursuant to which the underwriters or other purchasers
may be required to purchase any securities remaining unsubscribed for after such offering.
The
prospectus supplement relating to any subscription rights we offer, if any, will, to the extent applicable, include specific terms
relating to the offering, including some or all of the following:
|
●
|
the
price, if any, for the subscription rights;
|
|
●
|
the
exercise price payable for our common stock, preferred stock or debt securities upon the exercise of the subscription rights;
|
|
●
|
the
number of subscription rights to be issued to each stockholder;
|
|
●
|
the
number and terms of our common stock, preferred stock or debt securities which may be purchased per each subscription right;
|
|
●
|
the
extent to which the subscription rights are transferable;
|
|
●
|
any
other terms of the subscription rights, including the terms, procedures and limitations relating to the exchange and exercise
of the subscription rights;
|
|
●
|
the
date on which the right to exercise the subscription rights shall commence, and the date on which the subscription rights
shall expire;
|
|
●
|
the
extent to which the subscription rights may include an over-subscription privilege with respect to unsubscribed securities
or an over-allotment privilege to the extent the securities are fully subscribed; and
|
|
●
|
if
applicable, the material terms of any standby underwriting or purchase arrangement which may be entered into by us in connection
with the offering of subscription rights.
|
The
description in the applicable prospectus supplement of any subscription rights we offer will not necessarily be complete and will
be qualified in its entirety by reference to the applicable subscription rights certificate, which will be filed with the SEC
if we offer subscription rights. We urge you to read the applicable subscription rights certificate and any applicable prospectus
supplement in their entirety.
DESCRIPTION
OF UNITS
We
may issue units consisting of some or all of the securities described above, in any combination, including common stock, preferred
stock, warrants and/or debt securities. The terms of these units will be set forth in a prospectus supplement. The description
of the terms of these units in the related prospectus supplement will not be complete. You should refer to the applicable form
of unit and unit agreement for complete information with respect to these units.
LEGAL
MATTERS
Fenwick
& West LLP, Seattle, Washington, will issue an opinion about certain legal matters with respect to the securities. Any underwriters
or agents will be advised about legal matters relating to any offering by their own counsel.
EXPERTS
Marcum
LLP, independent registered public accounting firm, has audited our financial statements included in our Annual Report on Form
10-K for the year ended December 31, 2019, as set forth in their report, which is incorporated by reference in this prospectus
and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on Marcum LLP’s
report, given on their authority as experts in accounting and auditing.
Common
Stock
Preferred
Stock
Debt
Securities
Warrants
Subscription
Rights
Units
PROSPECTUS
,
2020
The
information in this prospectus supplement and the accompanying prospectus is not complete and may be changed. We may not sell
these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus
supplement and accompanying prospectus are not an offer to sell these securities, and we are not soliciting an offer to buy these
securities, in any jurisdiction where the offer or sale is not permitted.
SUBJECT
TO COMPLETION, DATED AUGUST 24, 2020
PROSPECTUS
SUPPLEMENT
Up
to $15,477,192
Common
Stock
We
have previously entered into an At-the-Market Sales Agreement, or the Sales Agreement, with Virtu Americas LLC, or Virtu, relating
to shares of our common stock, par value $0.001 per share, offered by this prospectus supplement and the accompanying prospectus.
In accordance with the terms of the Sales Agreement, from time to time we may offer and sell shares of our common stock having
an aggregate offering price of up to $15,477,192 through Virtu, acting as sales agent. As of August 24, 2020, we have sold 2,350,067
shares of our common stock for gross proceeds of $4.5 million under the Sales Agreement.
Our
common stock is traded on the Nasdaq Capital Market under the symbol “CWBR.” On August 21, 2020, the last reported
sale price of our common stock on the Nasdaq Capital Market was $1.40 per share.
Sales
of our common stock, if any, under this prospectus supplement and accompanying prospectus may be made in sales deemed to be an
“at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, or
the Securities Act. Subject to the terms of the Sales Agreement, Virtu is not required to sell any specific number or dollar amounts
of securities but will act as our sales agent using commercially reasonable efforts consistent with its normal trading and sales
practices, on mutually agreed terms between Virtu and us. There is no arrangement for funds to be received in any escrow, trust
or similar arrangement.
The
compensation to Virtu for sales of common stock sold pursuant to the Sales Agreement will be at a fixed commission rate of up
to 3.0% of the gross proceeds of any shares of common stock sold under the Sales Agreement. In connection with the sale of the
common stock on our behalf, Virtu will be deemed to be an “underwriter” within the meaning of the Securities Act and
the compensation of Virtu will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification
and contribution to Virtu against certain civil liabilities, including liabilities under the Securities Act.
Investing
in our common stock involves a high degree of risk. Please read the information contained in and incorporated by reference under
the heading “Risk Factors” beginning on page S-3 of this prospectus supplement, under the heading “Risk
Factors” beginning on page 3 of the accompanying prospectus, and the risk factors described in the documents that
are incorporated by reference into this prospectus supplement and the accompanying prospectus, as they may be amended, updated
or modified periodically in our reports filed with the Securities and Exchange Commission.
Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary
is a criminal offense.
The
date of this prospectus supplement is , 2020.
TABLE
OF CONTENTS
Prospectus
Supplement
Prospectus
We
have not, and Virtu has not, authorized any dealer, salesperson or other person to give any information or to make any representation
other than those contained in or incorporated by reference into this prospectus supplement, the accompanying prospectus or any
applicable free writing prospectus. You must not rely upon any information or representation not contained in or incorporated
by reference into this prospectus supplement, the accompanying prospectus or any applicable free writing prospectus as if we had
authorized it. This prospectus supplement, the accompanying prospectus and any applicable free writing prospectus do not constitute
an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate,
nor does this prospectus supplement, the accompanying prospectus or any applicable free writing prospectus constitute an offer
to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such
offer or solicitation in such jurisdiction. You should not assume that the information contained in this prospectus supplement,
the accompanying prospectus, the documents incorporated herein and therein by reference and any applicable free writing prospectus
is correct on any date after their respective dates, even though this prospectus supplement, the accompanying prospectus or an
applicable free writing prospectus is delivered or securities are sold on a later date. Our business, financial condition, results
of operations and cash flows may have changed since those dates.
ABOUT
THIS PROSPECTUS SUPPLEMENT
This
document is in two parts. The first part is this prospectus supplement, which describes the specific terms of this offering. The
second part, the accompanying prospectus, provides more general information, some of which may not apply to this offering. The
prospectus and prospectus supplement are part of a registration statement that we filed with the Securities and Exchange Commission,
or the SEC, utilizing a “shelf” registration process. Under the shelf registration process, we may from time to time
sell shares of our common stock having an aggregate offering price of up to $100,000,000 under this prospectus at prices and on
terms to be determined by market conditions at the time of the offering. Generally, when we refer to this “prospectus supplement,”
we are referring to both this prospectus supplement and the accompanying prospectus, as well as the documents incorporated by
reference herein and therein. If information in this prospectus supplement is inconsistent with the accompanying prospectus, you
should rely on this prospectus supplement. If any statement in one of these documents is inconsistent with a statement in another
document having a later date (for example, a document incorporated by reference in this prospectus), the statement in the document
having the later date modifies or supersedes the earlier statement. We further note that
the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is
incorporated by reference herein were made solely for the benefit of the parties to such agreement, including, in some cases,
for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty
or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly,
such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs.
You
should rely only on the information contained in or incorporated by reference in this prospectus supplement, the accompanying
prospectus, and any related free writing prospectus filed by us with the SEC. We have not, and Virtu has not, authorized anyone
to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely
on it. This prospectus supplement does not constitute an offer to sell or the solicitation of an offer to buy any securities other
than the securities described in this prospectus supplement or an offer to sell or the solicitation of an offer to buy such securities
in any circumstances in which such offer or solicitation is unlawful. You should assume that the information appearing in this
prospectus supplement, the accompany prospectus, the documents incorporated by reference herein and any related free writing prospectus
is accurate only as of their respective dates. Our business, financial condition, results of operations and prospects may have
changed materially since those dates.
Before
buying any of the common stock that we are offering, we urge you to carefully read this prospectus supplement, the accompanying
prospectus and any free writing prospectus and all of the information incorporated by reference herein and therein, as well as
the additional information described under the headings “Where You Can Find Additional Information” and “Incorporation
of Information by Reference.” These documents contain important information that you should consider when making your investment
decision.
As
used in this prospectus, “CohBar,” the “Company,” “we,” “our” or “us”
refers to CohBar, Inc. COHBARTM and other trademarks or service marks of CohBar, Inc. appearing in this prospectus
are the property of CohBar, Inc. Trade names, trademarks and service marks of other companies appearing in this prospectus are
the property of their respective holders.
PROSPECTUS
SUPPLEMENT SUMMARY
The
following summary is qualified in its entirety by, and should be read together with, the more detailed information and our consolidated
financial statements and related notes thereto appearing elsewhere or incorporated by reference in this prospectus supplement
and the accompanying prospectus. Before you decide to invest in our securities, you should read the entire prospectus supplement
and the accompanying prospectus carefully, including the risk factors and the financial statements and related notes included
or incorporated by reference in this prospectus supplement and the accompanying prospectus.
Company
Overview
CohBar,
Inc. is a clinical stage biotechnology company and a leader in the research and development of mitochondria based therapeutics,
or MBTs, an emerging class of drugs with the potential to treat a wide range of chronic and age-related diseases, including non-alcoholic
steatohepatitis, or NASH, obesity, cancer, fibrotic diseases including idiopathic pulmonary fibrosis, or IPF, acute respiratory
distress syndrome, or ARDS, including COVID-19 associated ARDS, type 2 diabetes mellitus, or T2D, and cardiovascular and neurodegenerative
diseases.
MBTs
originate from almost two decades of research by our founders, resulting in their discovery of a novel group of mitochondrial-derived
peptides, or MDPs encoded within the mitochondrial genome. Some of these naturally occurring MDPs and their analogs have demonstrated
a range of biological activity and therapeutic potential in research models across multiple diseases associated with aging.
Our
efforts have resulted in the identification of more than 100 previously unidentified peptides encoded within the mitochondrial
genome and generated over 1,000 analogs. Many of these MDPs and their analogs have demonstrated various degrees of biological
activity in cell based and/or animal models relevant to a wide range of diseases, such as NASH, obesity, cancer, fibrotic diseases
including IPF, T2D and cardiovascular and neurodegenerative diseases.
The
following are our future plans and expectations with respect to the advancement of our programs which are subject to, among other
risks, our receipt of positive clinical and preclinical results and sufficient project funding. In developing our CB4211 candidate
for NASH and obesity, we plan to complete pre-phase 2 work in 2021, and initiate a phase 2 study in 2022. In developing our antifibrosis
peptides for IPF and fibrotic diseases program, we expect to select a preclinical candidate by the end of 2020, and complete pre-IND
enabling activities and initiate a phase 1 study in 2021, with the goal of initiating a phase 2 study in 2022. In advancing our
apelin agonists for COVID-19 ARDS and ARDS program, we expect to nominate a clinical candidate and begin pre-IND work in 2021,
with the goal of initiating a phase 1 study in 2022 and a phase 2 study in 2023. In advancing our CXCR4 inhibitors for our cancer
and orphan diseases program, we expect to nominate a clinical candidate and begin pre-IND work in 2021, with the goal of initiating
a phase 1 study in 2022 and a phase 2 study in 2023.
Recent
Developments
In
August 2020, we entered into amendments, or Amendments, with certain holders of our 8% Unsecured Promissory Notes, as amended,
or the 2018 Notes, and Nontransferable Common Stock Purchase Warrants, as amended, or the 2018 Warrants. Pursuant to the Amendments,
the maturity date of the applicable 2018 Notes was extended from June 30, 2021 to June 30, 2022 and the expiration date of the
applicable 2018 Warrants was extended from March 29, 2022 to March 29, 2026. The exercise price of the 2018 Warrants was adjusted
from $5.30 per share to $2.00 per share. The terms of the applicable 2018 Notes were also amended to require that the holders
of such 2018 Notes participate in a future private offering of our securities, or Private Offering, upon terms substantially similar
to those offered to investors in a future primary offering of our securities. All principal and interest outstanding under the
applicable 2018 Notes will convert into our securities in the Private Offering, subject to legal and regulatory limitations. We
also granted an additional warrant to purchase a half share of our common stock per dollar of each participating 2018 Note holder’s
principal amount of the 2018 Notes with an exercise price of $2.00 per share and an expiration date of March 29, 2026, or the
New Warrants. The New Warrants will be exercisable beginning on the six-month anniversary of the date of issuance, and we granted
to the participating 2018 Note holders certain registration rights with respect to our securities issued in the Private Offering
and the shares of common stock underlying the New Warrants.
Corporate
Information
Our
Company was formed as a Delaware limited liability company on October 19, 2007. We converted to a Delaware corporation under the
provisions of the Delaware Limited Liability Company Act and the Delaware General Corporation Law on September 16, 2009. Our principal
executive offices are located at 1455 Adams Dr., Suite 2050, Menlo Park, CA 94025. Our telephone number is (650) 446-7888. We
maintain a website at www.cohbar.com. The information contained on, connected to or that can be accessed via our website is not
a part of, and is not incorporated into, this prospectus supplement and the inclusion of our website address in this prospectus
supplement is an inactive textual reference only. We have no subsidiaries.
We
are an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and
take advantage of certain exemptions from various public company reporting requirements. We
will cease being an emerging growth company on December 31, 2020. We are also a smaller reporting company as
defined in the Exchange Act. We may take advantage of certain of the scaled disclosures available to smaller reporting companies
for so long as our voting and non-voting common stock held by non-affiliates is less than $250.0 million measured on the last
on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0 million during the most recently
completed fiscal year and our voting and nonvoting common stock held by non-affiliates is less than $700.0 million measured on
the last business day of our second fiscal quarter.
THE
OFFERING
Common
stock offered by us
|
|
Shares
of our common stock having an aggregate offering price of up to $15,477,192. As of August 24, 2020, we have sold 2,350,067
shares of our common stock for gross proceeds of $4.5 million under the Sales Agreement.
|
|
|
|
Common
stock to be outstanding immediately after this offering(1)
|
|
Up
to 11,215,357 shares of common stock after the completion of this offering, assuming that we sell the maximum dollar value
of shares available to be sold in the offering at a price of $1.38 per share, which was the closing price of our common stock
on the Nasdaq Capital Market on August 20, 2020. The actual number of shares outstanding after this offering will vary depending
on the number of shares sold and issued and the sale prices of such shares.
|
|
|
|
Plan
of Distribution
|
|
“At
the market offering” that may be made from time to time through our sales agent, Virtu. See “Plan of Distribution”
in this prospectus supplement.
|
|
|
|
Use
of Proceeds
|
|
We
intend to use the net proceeds from this offering primarily for research and development, growth capital and general working
capital. See “Use of Proceeds” in this prospectus supplement.
|
|
|
|
Risk
Factors
|
|
Investing
in our common stock involves a high degree of risk, and the purchasers of our common stock may lose all or part of their investment.
Before deciding to invest in our securities, please carefully read the section entitled “Risk Factors,” and the
accompanying prospectus.
|
|
|
|
Nasdaq
Capital Market symbol
|
|
“CWBR”
|
The
number of shares of our common stock to be outstanding immediately after this offering as shown above is based on 45,645,326 shares
of common stock outstanding as of June 30, 2020 and excludes the following:
|
●
|
7,447,974
shares of common stock issuable upon exercise of options outstanding as of June 30, 2020, with a weighted average exercise
price of $2.06 per share;
|
|
●
|
4,887,223
shares of common stock issuable upon exercise of warrants outstanding as of June 30, 2020 at a weighted average exercise price
of $2.40 per share;
|
|
●
|
5,169,109
shares of common stock reserved and available for future issuance under our Amended and Restated 2011 Equity Incentive Plan
as of June 30, 2020;
|
|
●
|
500,000
shares of common stock reserved and available for future issuance under our Employee Stock Purchase Plan as of June 30, 2020;
and
|
|
●
|
any
shares to be issued following this offering to the 2018 Note holders in connection with the conversion of the 2018 Notes in
the Private Offering.
|
Except
as otherwise indicated, all information in this prospectus supplement assumes no exercise of outstanding options and no exercise
of the underwriters’ option to purchase additional shares of common stock.
RISK
FACTORS
Investing
in our securities involves a high degree of risk. You should carefully consider the risks described in the documents incorporated
by reference in this prospectus supplement and the accompanying prospectus, as well as other information we include or incorporate
by reference into this prospectus and any applicable prospectus supplement, before making an investment decision. Our business,
financial condition or results of operations could be materially adversely affected by the materialization of any of these risks.
The trading price of our securities could decline due to the materialization of any of these risks, and you may lose all or part
of your investment. This prospectus supplement and the documents incorporated herein by reference also contain forward-looking
statements that involve risks and uncertainties. Actual results could differ materially from those anticipated in these forward-looking
statements as a result of certain factors, including the risks described in the documents incorporated herein by reference, including
(i) our most recent annual report on Form 10-K which is on file with the SEC and is incorporated herein by reference, (ii) our
most recent quarterly reports on Form 10-Q, which are on file with the SEC and are incorporated by reference into this prospectus
supplement, and (iii) other documents we file with the SEC that are deemed incorporated by reference into this prospectus supplement.
These risk factors may be amended, supplemented or superseded from time to time by risk factors contained in other Exchange Act
reports that we file with the SEC, which will be subsequently incorporated herein by reference; by any other prospectus supplement;
or by a post-effective amendment to the registration statement of which this prospectus supplement forms a part. In addition,
new risks may emerge at any time and we cannot predict such risks or estimate the extent to which they may affect our financial
performance. For more information, see “Where You Can Find More Information,” “Incorporation By Reference”
and “Cautionary Statement Regarding Forward-Looking Statements.”
Additional
Risks Related to this Offering
Because
we have broad discretion in how we use the proceeds from this offering, we may use the proceeds in ways with which you disagree.
We
have not allocated specific amounts of the net proceeds from this offering for any specific purpose. Accordingly, our management
will have some flexibility in applying the net proceeds of this offering. You will be relying on the judgment of our management
with regard to the use of these net proceeds, and you will not have the opportunity, as part of your investment decision, to assess
whether the proceeds are being used appropriately. It is possible that the net proceeds will be invested in a way that does not
yield a favorable, or any, return for us. The failure of our management to use such funds effectively could have a material adverse
effect on our business, financial condition, operating results and cash flow.
You
will experience immediate dilution in the book value per share of the common stock you purchase.
The
offering price per share in this offering may exceed the net tangible book value per share of our common stock outstanding prior
to this offering. Assuming that an aggregate of 11,215,357 shares of our common stock are sold at a price of $1.38 per share,
the last reported sale price of our common stock on the Nasdaq Capital Market on August 20, 2020, for aggregate gross proceeds
of $15.5 million, and after deducting commissions and estimated offering expenses payable by us, you will experience immediate
dilution of $0.98 per share, representing the difference between our as adjusted net tangible book value per share as of June
30, 2020 after giving effect to this offering and the assumed offering price. The exercise of outstanding stock options and warrants
will result in further dilution of your investment. See “Dilution” for a more detailed discussion of the dilution
you will incur in connection with this offering.
You
may experience future dilution as a result of future equity offerings.
In
order to raise additional capital, we may at any time, including during the pendency of this offering, offer additional shares
of our common stock or other securities convertible into or exchangeable for our common stock at prices that may not be the same
as the price per share in this offering. We may sell shares or other securities in any other offering at a price per share that
is less than the price per share paid by investors in this offering, and investors purchasing shares or other securities in the
future could have rights superior to existing stockholders. The price per share at which we sell additional shares of our common
stock, or securities convertible or exchangeable into common stock, in future transactions may be higher or lower than the price
per share paid by investors in this offering.
The
actual number of shares we will issue under the Sales Agreement, at any one time or in total, is uncertain.
Subject
to certain limitations in the Sales Agreement and compliance with applicable law, we have the discretion to deliver a placement
notice to Virtu at any time throughout the term of the Sales Agreement. The number of shares that are sold by Virtu after delivering
a placement notice will fluctuate based on the market price of our common stock during the sales period and limits we set with
Virtu. Because the price per share of each share sold will fluctuate based on the market price of our common stock during the
sales period, it is not possible at this stage to predict the number of shares that will be ultimately issued.
The
common stock offered hereby will be sold in “at the market offerings,” and investors who buy shares at different times
will likely pay different prices.
Investors
who purchase shares in this offering at different times will likely pay different prices, and so may experience different outcomes
in their investment results. We will have discretion, subject to market demand, to vary the timing, prices and numbers of shares
sold, and there is no minimum or maximum sales price. Investors may experience a decline in the value of their shares as a result
of share sales made at prices lower than the prices they paid.
CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This
prospectus supplement, including “Prospectus Supplement Summary,” “Risk Factors” and “Use of Proceeds,”
the accompanying prospectus and the documents incorporated by reference herein contain forward-looking statements within the meaning
of the United States Private Securities Litigation Reform Act of 1995, or collectively, forward-looking statements. Forward-looking
statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs,
expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events
and trends, the economy and other future conditions. In some cases you can identify these statements by forward-looking words
such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,”
“intend,” “could,” “should,” “would,” “project,” “plan,”
“expect,” “goal,” “seek,” “future,” “likely” or the negative or plural
of these words or similar expressions. These forward-looking statements include, but are not limited to, the following:
|
●
|
our
future results of operations and financial position, business strategy, market size and potential growth opportunities;
|
|
|
|
|
●
|
preclinical
and clinical development activities;
|
|
|
|
|
●
|
efficacy
and safety profiles of our clinical candidates;
|
|
|
|
|
●
|
the
anticipated therapeutic properties of our MBT drug development candidates;
|
|
|
|
|
●
|
expectations
regarding our ability to effectively protect our intellectual property; and
|
|
|
|
|
●
|
expectations
regarding our ability to attract and retain qualified employees and key personnel.
|
Because
forward-looking statements relate to the future, they are subject to a number of risks, uncertainties and assumptions, which are
difficult to predict and many of which are outside of our control, including those described in “Risk Factors.” Moreover,
we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for
our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor,
or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements
we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in
this prospectus may not occur and actual results could differ materially and adversely from those anticipated or implied in the
forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated in
the forward-looking statements include, among other things, the following:
|
●
|
disruptions
resulting from the COVID-19 outbreak, or similar pandemics, that could severely impact our business, clinical trials and preclinical
studies;
|
|
|
|
|
●
|
whether
the results of our clinical trials of CB4211 will be predictive of the final results of the trial or results of early clinical
studies, and whether such results will be indicative of the results of future studies;
|
|
|
|
|
●
|
our
ability to obtain required regulatory approvals to develop and market our product candidates;
|
|
|
|
|
●
|
our
ability to raise additional capital on favorable terms;
|
|
|
|
|
●
|
our
ability to execute our research and development plan on time and on budget;
|
|
|
|
|
●
|
our
ability to obtain commercial partners;
|
|
|
|
|
●
|
our
ability, whether alone or with commercial partners, to successfully develop and commercialize a product candidate;
|
|
|
|
|
●
|
our
ability to identify and develop additional drug candidates; and
|
|
|
|
|
●
|
other
risk factors included under “Risk Factors” in this prospectus.
|
This
list is not exhaustive of the factors that may affect our forward-looking statements. You should not rely upon forward-looking
statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements
are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected
in the forward-looking statements will be achieved or occur. Any forward-looking statement made by us in this prospectus is based
only on information currently available to us and speaks only as of the date on which it is made. Moreover, except as required
by law, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements.
Except as required by applicable law, we undertake no obligation to update publicly any forward-looking statements for any reason
after the date of this prospectus to conform these statements to actual results or to changes in our expectations.
USE
OF PROCEEDS
We
may issue and sell shares of our common stock having aggregate sales proceeds of up to $15,477,192 from time to time. As of August
24, 2020, we have sold 2,350,067 shares of our common stock for gross proceeds of $4.5 million under the Sales Agreement. Because
there is no minimum offering amount required as a condition to close this offering, the actual total public offering amount, commissions
and proceeds to us, if any, are not determinable at this time. There can be no assurance that we will sell any shares under, or
fully utilize, the Sales Agreement with Virtu as a source of financing.
We
intend to use the net proceeds from this offering primarily for research and development, growth capital and general working capital.
We have not determined the amounts we plan to spend on any specific purpose or the timing of these expenditures. As a result,
our management will have broad discretion to allocate the net proceeds from this offering. Pending application of the net proceeds
as described above, we intend to invest the net proceeds to us from this offering in a variety of capital preservation investments,
including short-term, investment-grade and interest-bearing instruments.
DILUTION
If
you invest in our common stock, you will experience dilution to the extent of the difference between the price per share you pay
in this offering and the net tangible book value per share of our common stock immediately after this offering.
Our
net tangible book value as of June 30, 2020 was approximately $7.7 million, or $0.17 per share of common stock. Net
tangible book value per share as of June 30, 2020 is equal to our total tangible assets minus total liabilities as of that date,
all divided by the number of shares of common stock outstanding as of June 30, 2020. Dilution represents the difference between
the amount per share paid by purchasers of shares in this offering and the as-adjusted net tangible book value per share of our
common stock immediately after giving effect to this offering.
After
giving effect to the sale of shares of our common stock in the aggregate amount of $15.5 million in this offering at an assumed
offering price of $1.38 per share, which was the last reported sale price of our common stock on the Nasdaq Capital Market on
August 20, 2020, and after deducting commissions and estimated aggregate offering expenses payable by us, our as-adjusted net
tangible book value as of June 30, 2020 would have been approximately $22.7 million, or $0.40 per share of common stock. This
represents an immediate increase in net tangible book value per share of $0.23 to our existing stockholders and an immediate dilution
in net tangible book value per share of $0.98 to new investors purchasing common stock in this offering. The following table illustrates
this dilution on a per share basis to new investors participating in this offering.
Assumed public offering price per share
|
|
|
|
|
|
$
|
1.38
|
|
Net tangible book value per share as of June 30, 2020
|
|
$
|
0.17
|
|
|
|
|
|
Increase in net tangible book value per share after this offering
|
|
$
|
0.23
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As adjusted net tangible book value per share as of June 30, 2020, after this offering
|
|
|
|
|
|
$
|
0.40
|
|
|
|
|
|
|
|
|
|
|
Dilution in as adjusted net tangible book value per share to new investors
|
|
|
|
|
|
$
|
0.98
|
|
The
table above assumes, for illustrative purposes, that an aggregate of 11,215,357 shares of our common stock are sold at a price
of $1.38 per share, the last reported sale price of our common stock on the Nasdaq Capital Market on August 20, 2020, for aggregate
gross proceeds of $15.5 million. After giving effect to these transactions, we would have 56,860,683 shares of outstanding common
stock.
The
shares sold in this offering, if any, will be sold from time to time at various prices. An increase of $1.00 per share in the
price at which the shares are sold from the assumed offering price of $1.38 per share shown in the table above, assuming all of
our common stock in the aggregate amount of $15.5 million during the term of the Sales Agreement with Virtu is sold at that price,
would increase our as-adjusted net tangible book value per share after the offering to $0.44 per share, and would increase the
dilution in net tangible book value per share to new investors to $1.94 per share, after deducting commissions and estimated aggregate
offering expenses payable by us. A decrease of $1.00 per share in the price at which the shares are sold from the assumed offering
price of $1.38 per share shown in the table above, assuming all of our common stock in the aggregate amount of $15.5 million during
the term of the Sales Agreement with Virtu is sold at that price, would decrease our as-adjusted net tangible book value per share
after the offering to $0.26 per share and would decrease the dilution in net tangible book value per share to new investors to
$0.12 per share, after deducting commissions and estimated aggregate offering expenses payable by us. This information is supplied
for illustrative purposes only and may differ based on the actual offering price and the actual number of shares offered.
The
above discussion and table are based on 45,645,326 shares of common stock outstanding as of June 30, 2020 and excludes the following:
|
●
|
7,447,974
shares of common stock issuable upon exercise of options outstanding as of June 30, 2020, with a weighted average exercise
price of $2.06 per share;
|
|
●
|
4,887,223
shares of common stock issuable upon exercise of warrants outstanding as of June 30, 2020 at a weighted average exercise price
of $2.40 per share;
|
|
●
|
5,169,109
shares of common stock reserved and available for future issuance under our Amended and Restated 2011 Equity Incentive Plan
as of June 30, 2020;
|
|
●
|
500,000
shares of common stock reserved and available for future issuance under our Employee Stock Purchase Plan as of June 30, 2020;
and
|
|
●
|
any
shares to be issued following this offering to the 2018 Note holders in connection with the conversion of the 2018 Notes in
the Private Offering.
|
To
the extent that options or warrants outstanding as of June 30, 2020 have been or are exercised, investors purchasing shares in
this offering could experience further dilution. In addition, we may choose to raise additional capital due to market conditions
or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. To the extent
that additional capital is raised through the sale of equity or equity-based securities at prices per share that are less than
the net tangible book value per share at the respective dates of those sales, the issuance of these securities could result in
further dilution to our stockholders.
PLAN
OF DISTRIBUTION
We
have previously entered into an At-the-Market Sales Agreement, or the Sales Agreement, with Virtu Americas LLC, or Virtu, pursuant
to which we may issue and sell up to $15,477,192 shares of our common stock, $0.001 par value per share, through Virtu, acting
as sales agent. As of August 24, 2020, we have sold 2,350,067 shares of our common stock for gross proceeds of $4.5 million under
the Sales Agreement. This summary of the material provisions of the Sales Agreement does not purport to be a complete statement
of its terms and conditions. A copy of the Sales Agreement was filed as an exhibit to the Current Report on Form 8-K filed with
the SEC on May 27, 2020 and is incorporated by reference into the registration statement of which this prospectus supplement is
a part. See “Where You Can Find More Information” below.
Upon
delivery of a placement notice and subject to the terms and conditions of the Sales Agreement, Virtu may sell our common stock
by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under
the Securities Act, including sales made directly on the Nasdaq Capital Market or any other existing trading market for our common
stock. We or Virtu may suspend the offering of our common stock upon notice and subject to other conditions.
We
will pay Virtu in cash, upon each sale of our common stock pursuant to the Sales Agreement, a commission in an amount of up to
3.0% of the aggregate gross proceeds from each sale of our common stock. Because there is no minimum offering amount required
as a condition to close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not
determinable at this time. We have also agreed to reimburse Virtu for certain specified expenses, in an aggregate amount not exceeding
$50,000, including the fees and disbursements of its legal counsel. We estimate that the total expenses for the offering, excluding
compensation and reimbursements payable to Virtu under the terms of the Sales Agreement, will be approximately $60,000.
Settlement
for sales of common stock will occur on the second business day following the date on which any sales are made, or on another
date that is agreed upon by us and Virtu in connection with a particular transaction, in return for payment of the net proceeds
to us. Sales of our common stock as contemplated in this prospectus supplement will be settled through the facilities of The Depository
Trust Company or by such other means as we and Virtu may agree upon. There is no arrangement for funds to be received in an escrow,
trust or similar arrangement.
Virtu
will use its commercially reasonable efforts, consistent with its sales and trading practices, to solicit offers to purchase shares
of our common stock under the terms and subject to the conditions set forth in the Sales Agreement. In connection with the sale
of the common stock on our behalf, Virtu will be deemed to be an “underwriter” within the meaning of the Securities
Act, and the compensation of Virtu will be deemed to be underwriting commissions or discounts. We have agreed to provide indemnification
and contribution to Virtu against certain civil liabilities, including liabilities under the Securities Act.
The
offering of our common stock pursuant to the Sales Agreement will terminate upon the termination of the Sales Agreement as permitted
therein. We and Virtu may each terminate the Sales Agreement at any time upon ten days’ prior notice.
We
have agreed to indemnify Virtu and specified other persons against certain liabilities relating to or arising out of the Virtu’s
activities under Sales Agreement and to contribute to payments that Virtu may be required to make in respect of such liabilities.
Virtu
and its affiliates may in the future provide various investment banking, commercial banking and other financial services for us
and our affiliates, for which services they may in the future receive customary fees. To the extent required by Regulation M,
Virtu will not engage in any market making activities involving our common stock while the offering is ongoing under this prospectus
supplement.
This
prospectus supplement and the accompanying prospectus in electronic format may be made available on a website maintained by Virtu,
and Virtu may distribute this prospectus supplement and the accompanying prospectus electronically.
LEGAL
MATTERS
The
validity of the securities offered in this prospectus will be passed upon for us by Fenwick & West LLP, Seattle, Washington.
Virtu Americas LLC is being represented in connection with this offering by Cooley LLP, New York, New York.
EXPERTS
Our
consolidated financial statements as of December 31, 2019 and 2018, and for each of the years in the two-year period ended December
31, 2019, have been incorporated by reference herein and in the registration statement in reliance upon the reports of Marcum,
LLP, independent registered public accounting firm, incorporated by reference herein, and upon the authority of said firm as experts
in accounting and auditing.
INCORPORATION
OF INFORMATION BY REFERENCE
The
SEC allows us to “incorporate by reference” information from other documents that we file with it, which means that
we can disclose important information to you by referring you to those documents. The information incorporated by reference is
considered to be part of this prospectus supplement.
Information
in this prospectus supplement supersedes information incorporated by reference that we filed with the SEC prior to the date of
this prospectus supplement.
We
incorporate by reference into this prospectus supplement and the registration statement of which this prospectus supplement is
a part the following documents that we have filed with the SEC:
|
●
|
our
Annual Report on Form 10-K for the fiscal year ended December 31, 2019 filed with the SEC on March 12, 2020;
|
|
●
|
Quarterly
Reports on Form 10-Q for the quarters ended March 31, 2020, filed with the SEC on May 14, 2020, and June 30, 2020, filed with
the SEC on August 13, 2020;
|
|
●
|
Current
Reports on Form 8-K filed on March 30, 2020, May 13, 2020, May 27, 2020, June 18, 2020 and July 9, 2020;
|
|
●
|
our
Definitive Proxy Statement
on Schedule 14Afor our 2020 annual meeting of stockholders filed with the SEC on April 29, 2020; and
|
|
●
|
the
description of our common stock contained in our registration statement on Form 8-A filed with the SEC on December 13, 2017 under Section 12 of the Exchange Act, including any amendment or report filed
for the purpose of updating such description.
|
We
also incorporate by reference all documents that we file with the SEC on or after the date of this prospectus pursuant to Sections
13(a), 13(c), 14 or 15(d) of the Exchange Act and prior to the sale of all the securities registered hereunder or the termination
of the registration statement. Nothing in this prospectus shall be deemed to incorporate information furnished but not filed with
the SEC.
Any
statement contained in this prospectus supplement or in a document incorporated or deemed to be incorporated by reference in this
prospectus supplement shall be deemed to be modified or superseded for purposes of this prospectus supplement, the accompanying
prospectus to the extent that a statement contained herein or in the applicable prospectus supplement or in any other subsequently
filed document which also is or is deemed to be incorporated by reference modifies or supersedes the statement. Any statement
so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus supplement.
You
may request a copy of the filings incorporated herein by reference, including exhibits to such documents that are specifically
incorporated by reference, at no cost, by writing or calling us at the following address or telephone number:
Corporate
Secretary
Chief
Executive Officer
1455
Adams Dr., Suite 2050
Menlo
Park, CA 94025
(650)
446-7888
Statements
contained in this prospectus supplement as to the contents of any contract or other documents are not necessarily complete, and
in each instance you are referred to the copy of the contract or other document filed as an exhibit to the registration statement
or incorporated herein, each such statement being qualified in all respects by such reference and the exhibits and schedules thereto.
WHERE
YOU CAN FIND MORE INFORMATION
This
prospectus supplement and the accompanying prospectus are part of a registration statement on Form S-3 that we filed with the
SEC registering the securities that may be offered and sold hereunder. The registration statement, including exhibits thereto,
contains additional relevant information about us and these securities that, as permitted by the rules and regulations of the
SEC, we have not included in this prospectus supplement or the accompanying prospectus. A copy of the registration statement can
be obtained at the address set forth below or at the SEC’s website as noted below. You should read the registration statement,
including any applicable prospectus supplement, for further information about us and these securities.
We
file annual reports, quarterly reports, current reports, proxy statements and other information with the SEC under the Securities
Exchange Act of 1934, as amended. The SEC maintains an Internet website at http://www.sec.gov where you can access copies of most
of our SEC filings.
We
make our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports,
available free of charge on our corporate website at www.cohbar.com. The contents of our corporate website are not incorporated
into, or otherwise to be regarded as part of, this prospectus supplement.
Up
to $15,477,192
Common
Stock
PROSPECTUS
SUPPLEMENT
,
2020
PART II
INFORMATION NOT REQUIRED IN
PROSPECTUS
Item 14. Other Expenses of Issuance and Distribution
The following table sets forth estimated expenses in connection
with the issuance and distribution of the securities being registered:
SEC registration fee
|
|
$
|
3,583
|
|
FINRA fee
|
|
|
15,500
|
|
Nasdaq listing fee
|
|
|
*
|
|
Printing and engraving
|
|
|
*
|
|
Legal fees and expenses
|
|
|
*
|
|
Accounting fees and expenses
|
|
|
*
|
|
Transfer agent and registrar fees and expenses
|
|
|
*
|
|
Miscellaneous expenses
|
|
|
*
|
|
Total
|
|
$
|
*
|
|
|
*
|
These fees are calculated
based on the type of securities offered and the number of issuances and accordingly, cannot be estimated at this time.
|
Item 15. Indemnification of Officers and Directors
Section 145 of the Delaware General Corporation Law authorizes
a court to award, or a corporation’s board of directors to grant, indemnity to directors and officers under certain circumstances
and subject to certain limitations. The terms of Section 145 of the Delaware General Corporation Law are sufficiently broad to
permit indemnification under certain circumstances for liabilities, including reimbursement of expenses incurred, arising under
the Securities Act of 1933, as amended, or the Securities Act.
As permitted by the Delaware General Corporation Law, the Registrant’s
restated certificate of incorporation contains provisions that eliminate the personal liability of its directors for monetary damages
for any breach of fiduciary duties as a director, except liability for the following:
|
●
|
any breach of the director’s duty of loyalty to the Registrant or its stockholders;
|
|
●
|
acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;
|
|
●
|
under Section 174 of the Delaware General Corporation Law (regarding unlawful dividends or stock purchases); or
|
|
●
|
any transaction from which the director derived an improper personal benefit.
|
As permitted by the Delaware General Corporation Law, the Registrant’s
restated bylaws provide that:
|
●
|
the Registrant is required to indemnify its directors and executive officers to the fullest extent permitted by the Delaware General Corporation Law, subject to limited exceptions;
|
|
●
|
the Registrant may indemnify its other employees and agents as set forth in the Delaware General Corporation Law;
|
|
●
|
the Registrant is required to advance expenses, as incurred, to its directors and executive officers in connection with a legal proceeding to the fullest extent permitted by the Delaware General Corporation Law, subject to limited exceptions; and
|
|
●
|
the rights conferred in the restated bylaws are not exclusive.
|
The Registrant has entered, and intends to continue to enter,
into indemnification agreements with each of its directors and executive officers to provide these directors and executive officers
additional contractual assurances regarding the scope of the indemnification set forth in the Registrant’s restated certificate
of incorporation and restated bylaws and to provide additional procedural protections. At present, there is no pending litigation
or proceeding involving a director or executive officer of the Registrant for which indemnification is sought. The indemnification
provisions in the Registrant’s restated certificate of incorporation, restated bylaws and the indemnification agreements
entered into or to be entered into between the Registrant and each of its directors and executive officers may be sufficiently
broad to permit indemnification of the Registrant’s directors and executive officers for liabilities arising under the Securities
Act.
The Registrant currently carries liability insurance for its
directors and officers.
Item
16. Exhibits
The
exhibits listed below are filed (except where otherwise indicated) as part of this Registration Statement.
*
|
To be filed by amendment or as an exhibit to a report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended and incorporated herein by reference.
|
**
|
To be filed in accordance with the requirements of Section 305(b)(2) of the Trust Indenture Act of 1939 and Rule 5b-3 thereunder.
|
Item
17. Undertakings
(a)
The undersigned Registrant hereby undertakes:
(1)
To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
(i)
to include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;
(ii)
to reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent
post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set
forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if
the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high
end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Securities and Exchange
Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change
in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective
registration statement; and
(iii)
to include any material information with respect to the plan of distribution not previously disclosed in the registration statement
or any material change to such information in the registration statement;
provided,
however, that subparagraphs (i), (ii), and (iii) do not apply if the information required to be included in a post-effective
amendment by those paragraphs is contained in reports filed with or furnished to the Securities and Exchange Commission by the
Registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in
the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration
statement.
(2)
That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall
be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at
that time shall be deemed to be the initial bona fide offering thereof.
(3)
To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold
at the termination of the offering.
(4)
That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:
(i)
Each prospectus filed by the Registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as
of the date the filed prospectus was deemed part of and included in the registration statement; and
(ii)
Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance
on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information
required by Section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement
as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale
of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and
any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement
relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in
a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed
incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to
a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the
registration statement or prospectus that was part of the registration statement or made in any such document immediately prior
to such effective date.
(5)
That, for the purpose of determining liability of the Registrant under the Securities Act of 1933 to any purchaser in the initial
distribution of the securities, the undersigned Registrant undertakes that in a primary offering of securities of the undersigned
Registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser,
if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned Registrant
will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:
(i)
any preliminary prospectus or prospectus of the undersigned Registrant relating to the offering required to be filed pursuant
to Rule 424;
(ii)
any free writing prospectus relating to the offering prepared by or on behalf of the undersigned Registrant or used or referred
to by the undersigned Registrant;
(iii)
the portion of any other free writing prospectus relating to the offering containing material information about the undersigned
Registrant or its securities provided by or on behalf of the undersigned Registrant; and
(iv)
any other communication that is an offer in the offering made by the undersigned Registrant to the purchaser.
(b)
The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933,
each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act
of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the
Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration
statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the
initial bona fide offering thereof.
(c)
Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers, and
controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that
in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities
Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than
the payment by the Registrant of expenses incurred or paid by a director, officer, or controlling person of the Registrant in
the successful defense of any action, suit, or proceeding) is asserted by such director, officer, or controlling person in connection
with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by
controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against
public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.
(d)
If and when applicable, the Registrant hereby further undertakes to file an application for the purpose of determining the eligibility
of the trustee to act under subsection (a) of Section 310 of the Trust Indenture Act in accordance with the rules and regulations
prescribed by the Securities and Exchange Commission under Section 305(b)(2) of the Trust Indenture Act.
SIGNATURES
Pursuant
to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it
meets all of the requirements for filing on Form S-3 and has duly caused this Registration Statement to be signed on its behalf
by the undersigned, thereunto duly authorized, in the City of Menlo Park, State of California, on August 24, 2020.
|
COHBAR,
INC.
|
|
|
|
|
By:
|
/s/
Steven Engle
|
|
|
Steven
Engle
|
|
|
Chief
Executive Officer
|
POWER
OF ATTORNEY
KNOW
ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Steven Engle
and Jeffrey F. Biunno, and each of them, as his true and lawful attorneys-in-fact, proxies and agents, each with full power of
substitution, for him in any and all capacities, to sign any and all amendments to this registration statement (including post-effective
amendments or any abbreviated registration statement and any amendments thereto filed pursuant to Rule 462(b) increasing the number
of securities for which registration is sought), and to file the same, with all exhibits thereto and other documents in connection
therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact, proxies and agents full power and
authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully
for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact,
proxies and agents, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant
to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities
and on the dates indicated.
Signature
|
|
Title
|
|
Date
|
|
|
|
/s/
Steven Engle
Steven
Engle
|
|
Chief
Executive Officer and Director
(Principal
Executive Officer)
|
|
August
24, 2020
|
|
|
|
/s/
Jeffrey F. Biunno
Jeffrey
F. Biunno
|
|
Chief
Financial Officer, Treasurer and Secretary
(Principal
Accounting Officer and
Principal
Financial Officer)
|
|
August
24, 2020
|
|
|
|
/s/
Albion J. Fitzgerald
Albion
J. Fitzgerald
|
|
Chairman
of the Board of Directors
|
|
August
24, 2020
|
|
|
|
/s/
Jon L. Stern
Jon
L. Stern
|
|
Director
|
|
August
24, 2020
|
|
|
|
/s/
Nir Barzilai
Nir
Barzilai
|
|
Director
|
|
August
24, 2020
|
|
|
|
/s/
Pinchas Cohen
Pinchas
Cohen
|
|
Director
|
|
August
24, 2020
|
|
|
|
/s/
Phyllis Gardner
Phyllis
Gardner
|
|
Director
|
|
August
24, 2020
|
|
|
|
|
|
/s/
David Greenwood
David
Greenwood
|
|
Director
|
|
August
24, 2020
|
|
|
|
/s/
Misha Petkevich
Misha
Petkevich
|
|
Director
|
|
August
24, 2020
|
II-5
CohBar (NASDAQ:CWBR)
Historical Stock Chart
From Feb 2024 to Mar 2024
CohBar (NASDAQ:CWBR)
Historical Stock Chart
From Mar 2023 to Mar 2024